var title_f23_57_24464="Amelanotic melanoma 2";
var content_f23_57_24464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amelanotic melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24464=[""].join("\n");
var outline_f23_57_24464=null;
var title_f23_57_24465="Incisions radical vulvectomy";
var content_f23_57_24465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of incisions used for radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 613px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Radical vulvectomy&nbsp;via butterfly incision. (B) Modified radical vulvectomy: triple incision technique, a skin bridge is left between the radical vulvectomy and the groin incisions. (C) Modified radical vulvectomy: anterior horseshoe incision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24465=[""].join("\n");
var outline_f23_57_24465=null;
var title_f23_57_24466="Gram negative diplococci";
var content_f23_57_24466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    N gonorrhoeae stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of Neisseria gonorrhoeae in urethral exudate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McClatchey KD M.D., D.D.S. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24466=[""].join("\n");
var outline_f23_57_24466=null;
var title_f23_57_24467="Gout";
var content_f23_57_24467=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Gout (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/57/24467/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24467/contributors\" id=\"au99\">",
"       Michael A Becker, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/57/24467/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24467/contributors\" id=\"se4166\">",
"       H Ralph Schumacher, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/57/24467/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24467/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?23/57/24467?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GOUT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Gout is a painful and debilitating condition that develops in some people who have chronically high blood levels of urate (commonly referred to as uric acid). Not everyone with high blood urate levels (called hyperuricemia) develops gout; up to two-thirds of individuals with hyperuricemia never develop symptoms. It is unclear why some people with hyperuricemia develop gout while others do not.",
"    </p>",
"    <p>",
"     Although the joints are the most commonly affected part of the body, uric acid or urate crystals can be deposited in the kidney or urinary tract, causing kidney stones and occasionally impairing kidney function. Kidney stones caused by uric acid crystals occur in approximately 15 percent of people with gout. This compares with an 8 percent risk of kidney stones in people without gout.",
"    </p>",
"    <p>",
"     Gout is different than pseudogout, which is discussed in a separate topic review. Pseudogout is a form of arthritis that develops in some people in response to the presence of calcium pyrophosphate dihydrate (CPPD) crystals. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"      \"Patient information: Pseudogout (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GOUT RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Gout most commonly first develops in men between ages of 30 and 45 and in women between 55 and 70. In both men and women, gout is particularly common in individuals over 65 years of age. It is estimated that gout affects approximately 2 percent of people in the United States.",
"    </p>",
"    <p>",
"     The following characteristics increase the risk of developing gout",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     precipitating flares in established gout.",
"    </p>",
"    <p>",
"     Increase the risk of developing gout:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Obesity",
"      </li>",
"      <li>",
"       High blood pressure",
"      </li>",
"      <li>",
"       Injury or recent surgery",
"      </li>",
"      <li>",
"       Fasting",
"      </li>",
"      <li>",
"       Consuming excessive amounts of alcohol (particularly beer, whiskey, gin, vodka, and rum) on a regular basis",
"      </li>",
"      <li>",
"       Overeating",
"      </li>",
"      <li>",
"       Ingesting diets containing large amounts of meat, seafood, and high fructose corn syrup-containing beverages, such as non-diet sodas",
"      </li>",
"      <li>",
"       Taking medications that affect blood levels of urate (especially diuretics)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Precipitate gout flares in established gout:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Injury or recent surgery",
"      </li>",
"      <li>",
"       Fasting",
"      </li>",
"      <li>",
"       Consuming excessive amounts of alcohol",
"      </li>",
"      <li>",
"       Overeating",
"      </li>",
"      <li>",
"       Taking medications that affect blood levels of urate",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      GOUT SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Gout attacks cause sudden severe joint pain, often with redness, swelling, and tenderness of the joint. Although an attack typically affects a single joint, some people develop a few inflamed joints at the same time. The pain and inflammation are worst within several hours and generally improve completely over a few days to several weeks, even if untreated. It is not clear how the body &ldquo;turns off&rdquo; a gout attack.",
"    </p>",
"    <p>",
"     The characteristic pain and inflammation of gout develop when white blood cells and cells in the joint linings attempt to surround and digest urate crystal deposits. These cells recognize the crystal deposits as foreign material and release chemical signals that contribute to the pain, swelling, and redness associated with a gout attack.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      PHASES OF GOUT",
"     </span>",
"    </p>",
"    <p>",
"     There are three main phases of gout: acute gouty arthritis, intercritical gout, and chronic tophaceous gout.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Acute gouty arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Attacks of gout usually involve a single joint, most often the big toe or knee. This attack is known as acute gouty arthritis. People with osteoarthritis in the fingers may experience their first gout attacks in the fingers rather than the toes or knees.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Intercritical period",
"     </span>",
"     &nbsp;&mdash;&nbsp;The time between gout attacks is known as the intercritical period. A second attack typically occurs within two years, and additional attacks may occur thereafter. If gout is untreated over a period of several years, the time between attacks may shorten, and attacks may become increasingly severe and prolonged. Over time, the attacks can begin to involve multiple joints at once and may be accompanied by fever.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Chronic tophaceous gout",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have repeated attacks of gout over many years can develop tophaceous gout. This designation describes the accumulation of large numbers of urate crystals in masses called tophi that appear over time in joints, bursae, bones, and cartilage or under the skin. Tophi may cause erosion of the bone and eventually joint damage and deformity.",
"    </p>",
"    <p>",
"     The presence of tophi near the knuckles or small joints of the fingers can be a distressing cosmetic problem. Tophi are usually not painful or tender. However, they can become inflamed and can cause symptoms like those of an acute gouty attack (",
"     <a class=\"graphic graphic_picture graphicRef64367 \" href=\"UTD.htm?24/37/25183\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Tophaceous gout was more common in the past, when treatment for hyperuricemia was unavailable. Certain groups are still at risk for tophaceous gout, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       People who are treated with cyclosporine after organ transplantation",
"      </li>",
"      <li>",
"       Those who cannot tolerate or do not receive adequate doses of medications to treat hyperuricemia (for example, due to kidney failure or drug allergy)",
"      </li>",
"      <li>",
"       Women who are postmenopausal, especially those taking a diuretic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The risk factors listed previously for gout can also contribute to the development of tophaceous gout. (See",
"     <a class=\"local\" href=\"#H2\">",
"      'Gout risk factors'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      GOUT COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     People with gout are at increased risk of developing kidney stones. Uric acid crystals can collect in the urinary tract and form a stone. If a stone is large enough, it can block one of the tubes (ureters) that carry urine from the kidney to the bladder and out of the body.",
"    </p>",
"    <p>",
"     Rarely, urate crystals collect in the kidney tissue itself, where they can cause inflammation and scar tissue, which reduce kidney function. Medications that increase the amount of uric acid excreted by the kidneys may increase the risk of developing kidney stones.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      GOUT DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     There are many illnesses that can cause joint pain and inflammation. Gout is strongly suspected if a person has an acute attack of joint pain, followed by a period in which there are no symptoms. It is important to confirm the diagnosis of gout to ensure that potentially harmful medications are not taken unnecessarily over a prolonged period of time.",
"    </p>",
"    <p>",
"     The best way to diagnose gout is to examine synovial fluid from an affected joint to look for urate crystals in the sample. To obtain the fluid, the provider uses a needle and syringe to withdraw a small amount of fluid from inside the joint. Tophi located just beneath the skin can also be sampled with a needle to diagnose tophaceous gout.",
"    </p>",
"    <p>",
"     However, some clinicians do not have the facilities to check for urate crystals in the synovial fluid when symptoms are present. In this case, the tentative diagnosis is based upon a person's symptoms and a physical examination. Criteria for suspecting gout include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pain and inflammation involving one joint at a time, especially the joint at the base of the large toe",
"      </li>",
"      <li>",
"       Complete resolution of symptoms between attacks",
"      </li>",
"      <li>",
"       Blood testing showing high levels of urate",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      TREATMENT OF GOUT ATTACKS",
"     </span>",
"    </p>",
"    <p>",
"     The goal of treatment of flares of gouty arthritis is to reduce pain and inflammation quickly and safely. It may be necessary to use more than one drug to achieve this goal. Deciding which medication to use is based upon several factors, including a person's risk of bleeding, his kidney health, and whether there is a past history of an ulcer in the stomach or small intestine. Antiinflammatory medications are the best treatment for acute gout attacks and are best started early in the course of an attack.",
"    </p>",
"    <p>",
"     People with a history of gout should keep medication on hand to treat an attack because early treatment is an important factor in determining how long it takes to decrease the pain and severity of an attack.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Nonsteroidal antiinflammatory drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) work to reduce swelling in a joint and include ibuprofen (Advil&reg;, Motrin&reg;), naproxen (Aleve&reg;, Anaprox&reg;), and indomethacin (Indocin&reg;). Among the NSAIDs, naproxen is considered one of the safer medications with regard to cardiovascular side effects and has documented efficacy in acute gout. NSAIDs are generally recommended for people who have no history of kidney or liver disease, who have no bleeding problems, who do not use anticoagulant medications (blood thinners such as warfarin (Coumadin&reg;)), and who have no history of a stomach or duodenal ulcer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     NSAIDs are most effective in the treatment of a gout attack when they are started as soon as possible, before the attack is full blown. People who have had previous attacks may start taking an NSAID at the first signs of a recurrence.",
"    </p>",
"    <p>",
"     Although aspirin is an NSAID, it is not usually recommended for the treatment of gout because, depending upon the dose used, it can raise or lower urate levels in the blood.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Colchicine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colchicine may be prescribed instead of an NSAID. Colchicine does not increase the risk of ulcers, has no known interaction with anticoagulants, and, in proper doses, does not affect kidney function. However, colchicine can have bothersome side effects, including diarrhea, nausea, vomiting, and crampy abdominal pain. For this reason, colchicine is generally reserved for patients who cannot tolerate NSAIDs. Lower doses of colchicine than formerly used have been shown to be as effective for acute gout as the higher doses recommended in the past, and the gastrointestinal side effects have been much less of a problem. Some people have a great deal of success with colchicine and do not have side effects; colchicine might be used first for this group. Colchicine is generally taken as a pill, and the intravenous preparation is avoided, even if available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Steroids, also known more properly as glucocorticoids or corticosteroids, are effective antiinflammatory agents. Commonly used oral steroids include prednisone, prednisolone, and methylprednisolone.",
"    </p>",
"    <p>",
"     Steroids may be used if NSAIDs and colchicine cannot be used. They may be injected directly into the affected joint (called an intraarticular injection) or they can be given as pills or by intramuscular injection. People who have multiple affected joints or who cannot take NSAIDs or colchicine may be given oral steroids. However, there is an increased risk of recurrent gout attack (called a rebound attack) in people who take oral steroids. For this reason, steroids should be tapered slowly over a period of at least 7 to 14 days.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PROPHYLACTIC GOUT THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Prophylactic therapy aims to prevent or reduce the occurrence of acute flares of gouty arthritis. Colchicine is usually recommended as prophylactic therapy; it is taken daily at low doses to avoid gastrointestinal side effects. Colchicine reduces the frequency of acute gout attacks, particularly while starting drugs that lower urate levels.",
"    </p>",
"    <p>",
"     Prophylactic colchicine is not usually used as a long-term (years) treatment but is a helpful bridge as a person progresses from an acute flare to preventive therapy. Although not nearly as well-documented as colchicine, daily NSAIDs are sometimes used for prophylactic therapy and may have an advantage (because of pain relieving properties) for people who also have osteoarthritis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      PREVENTIVE GOUT THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Therapy to prevent gout may include medications and dietary changes that can be used long-term to lower urate levels and to prevent the progression of gout. Progressive gout can cause bone destruction and deformity (gouty arthropathy), disability, kidney stone formation, and, possibly, kidney damage. People who have one or more of these complications are strongly encouraged to take a urate-lowering treatment.",
"    </p>",
"    <p>",
"     Not everyone with gout will require preventive therapy; those fortunate few who have rare or mild attacks are often able to manage their gout by treating the acute attacks alone. On the other hand, people with increasingly frequent gout flares, with flares that are unusually prolonged, painful,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     disabling, or with unusually high blood urate levels are generally encouraged to take preventive therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Urate-lowering (antihyperuricemic) medications lower urate levels by helping to eliminate or by decreasing production of uric acid. Antihyperuricemic therapy is usually started after a gout attack has resolved. People who take their medication regularly and lower their urate levels eventually experience fewer attacks. At present, it is recommended that preventive therapy be continued indefinitely because there is no benefit to taking a break from medication.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Probenecid increases the efficiency of uric acid excretion by the kidney and is called a uricosuric drug. Benzbromarone is a more potent uricosuric drug but is not available in the United States. Both drugs can cause side effects, including rash, upset stomach, and kidney stone formation.",
"      </li>",
"      <li>",
"       Losartan is used to treat high blood pressure but also has a useful, though weak, urate-lowering effect, as does the lipid-lowering drug fenofibrate.",
"      </li>",
"      <li>",
"       Allopurinol (Alloprim&reg;, Zyloprim&reg;) and febuxostat (Uloric&reg;) work by preventing the formation of uric acid. Allopurinol is the most commonly used drug for lowering urate levels in gout. Allopurinol can cause side effects, including rash, lowered white cell and platelet counts, diarrhea, and fever, although these problems occur in a relatively small percentage of patients. There has been controversy as to whether the dose of allopurinol needs to be reduced in people with impaired kidney function, but no such dose-lowering concern is present with febuxostat when used at the approved doses. Periodic measurement of liver function is recommended during treatment with febuxostat and with allopurinol.",
"      </li>",
"      <li>",
"       Pegloticase (Krystexxa&reg;) works by breaking down urate into allantoin, an end product that is more easily disposed. Pegloticase is given by repeated intravenous infusions and can lower urate levels rapidly and profoundly. This biological agent is expensive and may cause allergic-like infusion reactions, some of which can be severe. For these reasons, it is recommended that pegloticase use be limited to patients with advanced gout that cannot be controlled with oral urate-lowering therapies.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Lowering urate levels to a goal range is a process that should take a number weeks or months to achieve. During this period, doses of the uric acid-lowering medications should be gradually adjusted to meet the goal (usually a blood uric acid level &lt;6",
"     <span class=\"nowrap\">",
"      mg/dL).",
"     </span>",
"     Very rapid urate lowering can cause more frequent acute flares of gout. Increased fluids are recommended during this time (at least two liters per day are recommended).",
"    </p>",
"    <p>",
"     The prophylactic therapy (colchicine or NSAIDs) (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Prophylactic gout therapy'",
"     </a>",
"     above) may be discontinued when blood levels of urate are normal and have been stable for about six months. Longer prophylactic therapy may be needed in some patients, especially those with tophi. Blood levels of urate are monitored periodically to ensure that the goal urate level is maintained.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Dietary changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changing your diet may reduce the frequency of gout attacks. Because obesity is a risk factor for gout, as well as for many other health conditions (heart disease, diabetes, high blood pressure), losing weight is an important goal. However, starvation or fad diets are not recommended [",
"     <a class=\"abstract\" href=\"UTD.htm?23/57/24467/abstract/1\">",
"      1",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Diet guidelines for patients with gout have changed over time, and it is not completely clear which combination of foods is best. The current recommendations are shown in the table (",
"     <a class=\"graphic graphic_table graphicRef68669 \" href=\"UTD.htm?30/9/30875\">",
"      table 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     You are encouraged to eat and drink:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Low-fat dairy products",
"      </li>",
"      <li>",
"       Foods made with complex carbohydrates (whole grains, brown rice, oats, beans)",
"      </li>",
"      <li>",
"       A moderate amount of wine (up to two 5 ounce servings per day [about 300 mL per day] is not likely to increase the risk of a gout attack)",
"      </li>",
"      <li>",
"       Coffee (may decrease serum uric acid levels)",
"      </li>",
"      <li>",
"       Vitamin C (500 mg per day has a mild urate-lowering effect)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Changes in diet are often recommended along with medications. Making changes in your diet, without taking a medicine, is not likely to make a big difference in your blood urate levels; following a very strict gout diet only lowers blood urate levels slightly (15 to 20 percent).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498670751\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H437740\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=see_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/21/338?source=see_link\">",
"      Patient information: Ganglion cyst (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H437747\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=see_link\">",
"      Hyperuricemia and gout in renal transplant recipients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28344?source=see_link\">",
"      Pathophysiology of gouty arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"      Prevention of recurrent gout",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link\">",
"      Treatment of acute gout",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (301) 496-8188",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nih.gov/niams/\">",
"        www.nih.gov/niams/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (404) 633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (800) 283-7800",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?23/57/24467/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?23/57/24467?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24467/abstract/1\">",
"      Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24467/abstract/2\">",
"      Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010; 22:165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f23_57_24467=[""].join("\n");
var outline_f23_57_24467=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GOUT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GOUT RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           GOUT SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           PHASES OF GOUT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           GOUT COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           GOUT DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           TREATMENT OF GOUT ATTACKS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PROPHYLACTIC GOUT THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           PREVENTIVE GOUT THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/37/25183\" title=\"picture 1\">",
"           Inflamed tophaceous gout PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?30/9/30875\" title=\"table 1\">",
"           Gout diet PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f23_57_24468="Argon plasma coagulation in the management of airway disease";
var content_f23_57_24468=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Argon plasma coagulation in the management of airway disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24468/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24468/contributors\">",
"     Francis D Sheski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24468/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24468/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24468/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24468/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/57/24468/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous modalities exist to treat airway obstruction including electrosurgery, laser photo-resection, mechanical debridement, cryotherapy, photodynamic therapy, and brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Argon plasma coagulation (APC) is an electrosurgical technique used to resect an obstructing lesion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to achieve hemostasis. In this topic review, the history, principles, equipment, and techniques of APC are discussed. In addition, the indications, contraindications, and complications of APC are presented. The use of APC in the management of gastrointestinal bleeding is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;APC was developed more than twenty years ago to improve surgical hemostasis. In the early 1990s, a flexible probe was introduced that facilitated its use during endoscopic procedures. APC was initially used during gastrointestinal endoscopy to achieve hemostasis during polypectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/3\">",
"     3",
"    </a>",
"    ]. Its use gradually expanded to include debulking esophageal tumors, removing tissue that had grown into gastrointestinal stents, otolaryngologic procedures, and dermatologic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. More recently, APC has been used during bronchoscopic procedures to debulk malignant airway tumors, control hemoptysis, remove granulation tissue from stents or anastomoses, and treat a variety of other benign disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the procedure, the equipment should be checked and its settings confirmed. In addition, a grounding pad should be placed on the patient's lower back or flank. Reasonable initial settings are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef77312 \" href=\"UTD.htm?7/52/8012\">",
"     table 1",
"    </a>",
"    ). We suggest using an initial power of 30 Watts and an initial argon flow rate of 0.8 to 1",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    Typical settings to which the operator may advance include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Applied power &ndash; 30 to 80 Watts",
"     </li>",
"     <li>",
"      Application time &ndash; less than 2 to 3 seconds",
"     </li>",
"     <li>",
"      Argon flow rate &ndash; 0.3 to 2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the patient is sufficiently sedated, flexible bronchoscopy is performed and the target lesion is identified. A flexible probe, which is usually 1.5 or 2.3 mm in diameter and 220 cm in length, is then passed through the instrument channel of the bronchoscope and advanced until the location of its tip meets three criteria (",
"    <a class=\"graphic graphic_picture graphicRef72597 \" href=\"UTD.htm?0/19/319\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The probe tip should be several centimeters beyond the bronchoscope's tip. This insures that the bronchoscope will not be burned.",
"     </li>",
"     <li>",
"      The probe tip should be within 1 cm of the target lesion. The electric current will not be conducted if the probe is further from the target lesion (ie, the electrical circuit will be open).",
"     </li>",
"     <li>",
"      The probe tip should not contact the target lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Argon gas is expelled from the probe and then a high voltage electric current is passed along the probe. When the electric current contacts the argon gas, the argon gas becomes ionized and conducts a monopolar current to the target lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/11\">",
"     11",
"    </a>",
"    ]. This argon plasma is applied to the surface in 1 to 3 second bursts. The heat produced denatures protein and evaporates intra- and extracellular water. The net effect is tissue destruction and coagulation.",
"   </p>",
"   <p>",
"    To debulk an obstructing lesion, the eschar is removed (eg, with forceps or a cryotherapy probe) and then APC is applied to the underlying fresh tissue. This is repeated until the tumor is debulked sufficiently. The depth and volume of tissue impacted depends on the voltage applied to the gas (ie, the applied power) and the duration (ie, the application time). As an example, the depth of penetration is less than 5 mm when the applied power is between 40 and 120 watts and the application time is less than or equal to two seconds.",
"   </p>",
"   <p>",
"    There are several issues of which clinicians should be mindful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When brisk bleeding complicates the procedure, increasing the argon flow rate may blow blood away from the source, thereby providing better visualization of the culprit lesion.",
"     </li>",
"     <li>",
"      An endotracheal tube may provide better airway control for patients who are tenuous or whose procedure may be complicated.",
"     </li>",
"     <li>",
"      APC can be performed with flexible or rigid bronchoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine monitoring and care is provided before, during, and after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for APC is resection of an obstructing airway lesion that is associated with dyspnea, hemoptysis, cough, or postobstructive pneumonia. Such resections are only palliative if the lesion is malignant. Characteristics of lesions that are associated with improvement of a patient's quality of life following palliative resection include polypoid shape, large endobronchial component, location in the trachea or a mainstem bronchus, and a short length. It is also favorable if the airway lumen can be visualized beyond the lesion and the distal lung is still functional.",
"   </p>",
"   <p>",
"    Whether APC can cure early lung cancer is not fully established. Endobronchial electrocautery, an alternative type of electrosurgery, has been shown to cure early lung cancer, which suggests that APC may do the same. Less common indications for APC include benign polyp removal, hemostasis, and debridement of granulation tissue around endobronchial stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled trials have been published that compare the various modalities that can perform endobronchial procedures. As a result, current practice is based upon local influences, available resources and equipment, the bronchoscopist's training and preferences, and uncontrolled studies. Examples of uncontrolled studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of 364 patients who underwent APC (482 procedures) reported a success rate of 67 percent, defined as hemostasis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      full or partial airway recanalization [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/6\">",
"       6",
"      </a>",
"      ]. The most common indications were airway obstruction (51 percent) and hemostasis (33 percent), of which malignancy was the underlying cause in nearly 90 percent. Of note, rigid bronchoscopy was used in 90 percent of the interventions.",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 60 patients who underwent APC (70 procedures), treatment was immediately successful in 59 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/9\">",
"       9",
"      </a>",
"      ]. All of the patients had either hemoptysis or airway obstruction, with treatment success defined as resolution of hemoptysis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased airway obstruction. Hemoptysis did not recur over a mean follow up of 97 days and improved dyspnea persisted over a mean follow up of 53 days. Malignant disease existed in 95 percent of patients, and all of the procedures were performed with flexible bronchoscopy. A similar study of 47 patients reported a success rate of 92 percent, which was maintained over a mean follow up of 6.7 months [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/7\">",
"       7",
"      </a>",
"      ]. However, an average of more than three sessions per patient was required to achieve this result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the above studies focused on APC in patients with manifestations of malignant airway disease, APC has successfully treated benign disorders such as granulation tissue due to stents or airway anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/6,8,12\">",
"     6,8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success rates appear to be similar among APC, electrocautery, laser photo-resection (eg, Nd:YAG laser), cryotherapy, brachytherapy, and photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. Among these modalities, only APC, electrocautery, and laser photo-resection can remove tissue rapidly and, therefore, have an immediate effect. APC is superior to electrocautery and laser photo-resection in achieving hemostasis. The three modalities that are most commonly used with a flexible bronchoscope are compared in the table (",
"    <a class=\"graphic graphic_table graphicRef72854 \" href=\"UTD.htm?22/6/22635\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of APC are infrequent (less than 1 percent of procedures). They include airway burn and airway perforation, which can cause pneumomediastinum, subcutaneous emphysema, and pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/6\">",
"     6",
"    </a>",
"    ]. Gas embolism has also been described in a case series, leading to three cases of cardiovascular collapse and one case of death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24468/abstract/14\">",
"     14",
"    </a>",
"    ]. In all of the cases, the argon flow rate was within the suggested range, but gas bubbles were seen in the left ventricle during transesophageal echocardiography. The authors believe that the gas embolized via the bronchial veins, since APC was performed in bronchi and APC in the trachea can lead to gas bubbles in the right heart via systemic veins.",
"   </p>",
"   <p>",
"    Ignition of a non-metallic stent and electrical shock are theoretical complications. Massive bleeding may occur during tumor resection, although this has not been reported. A burned bronchoscope has also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain steps may decrease the risk of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limiting the inspired oxygen concentration, the applied power (less than 80 Watts), and the application time (less than 5 seconds) probably minimizes the risk of airway perforation or fire.",
"     </li>",
"     <li>",
"      Keeping the probe tip several centimeters away from any combustible material likely prevents airway fire. Similarly, keeping the probe tip several centimeters away from the bronchoscope tip probably prevents the bronchoscope from being burned.",
"     </li>",
"     <li>",
"      Placing a grounding pad on the patient and keeping the probe tip away from the bronchoscope tip may decrease the chance of electrical shock.",
"     </li>",
"     <li>",
"      Maintaining the argon flow rate (&lt;2",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      may lessen the chance of gas embolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Argon plasma coagulation (APC) was developed more than twenty years ago to improve surgical hemostasis. More recently, APC has been used during bronchoscopic procedures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      APC can be used during flexible or rigid bronchoscopy. When using flexible bronchoscopy, once the target lesion is identified, a flexible probe is passed through the instrument channel of the bronchoscope and advanced until the probe tip is several centimeters beyond the bronchoscope's tip and within 1 cm, but not contacting, the target lesion. The argon gas then conducts an electrical current to the target lesion which causes tissue destruction and hemostasis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indication for APC is resection of an obstructing airway lesion that is associated with dyspnea, hemoptysis, cough, or postobstructive pneumonia. Alternative indications include benign polyp removal, hemostasis, and debridement of granulation tissue around endobronchial stents. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No controlled trials have been published that compare the various modalities that can perform endobronchial procedures. As a result, current practice is based upon local influences, available resources and equipment, the bronchoscopist's training and preferences, and uncontrolled studies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been determined that a patient is to undergo endobronchial resection of an obstructing malignant airway lesion, the choice of modality should be based on the bronchoscopist's expertise. Acceptable techniques include APC, endobronchial electrocautery, laser photo-resection (eg, Nd:YAG laser), cryotherapy, photodynamic therapy, and brachytherapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Comparison'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of APC are infrequent, occurring in fewer than 1 percent of procedures. Strategies exist that may decrease the likelihood of a complication. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/1\">",
"      Turner JF Jr, Wang KP. Endobronchial laser therapy. Clin Chest Med 1999; 20:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/2\">",
"      Sheski FD, Mathur PN. Cryotherapy, electrocautery, and brachytherapy. Clin Chest Med 1999; 20:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/3\">",
"      Grund KE, Storek D, Farin G. Endoscopic argon plasma coagulation (APC) first clinical experiences in flexible endoscopy. Endosc Surg Allied Technol 1994; 2:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/4\">",
"      Bergler W, H&ouml;nig M, G&ouml;tte K, et al. Treatment of recurrent respiratory papillomatosis with argon plasma coagulation. J Laryngol Otol 1997; 111:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/5\">",
"      Brand CU, Blum A, Schlegel A, et al. Application of argon plasma coagulation in skin surgery. Dermatology 1998; 197:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/6\">",
"      Reichle G, Freitag L, Kullmann HJ, et al. [Argon plasma coagulation in bronchology: a new method--alternative or complementary?]. Pneumologie 2000; 54:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/7\">",
"      Crosta C, Spaggiari L, De Stefano A, et al. Endoscopic argon plasma coagulation for palliative treatment of malignant airway obstructions: early results in 47 cases. Lung Cancer 2001; 33:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/8\">",
"      Keller CA, Hinerman R, Singh A, Alvarez F. The use of endoscopic argon plasma coagulation in airway complications after solid organ transplantation. Chest 2001; 119:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/9\">",
"      Morice RC, Ece T, Ece F, Keus L. Endobronchial argon plasma coagulation for treatment of hemoptysis and neoplastic airway obstruction. Chest 2001; 119:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/10\">",
"      Vonk-Noordegraaf A, Postmus PE, Sutedja TG. Bronchoscopic treatment of patients with intraluminal microinvasive radiographically occult lung cancer not eligible for surgical resection: a follow-up study. Lung Cancer 2003; 39:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/11\">",
"      Platt RC. Argon plasma electrosurgical coagulation. Biomed Sci Instrum 1997; 34:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/12\">",
"      Colt, HG. Bronchoscopic resection of Wallstent-associated granulation tissue using argon plasma coagulation. J Bronchol 1998; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/13\">",
"      Sutedja TG, Postmus PE. Photodynamic therapy in lung cancer. A review. J Photochem Photobiol B 1996; 36:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24468/abstract/14\">",
"      Reddy C, Majid A, Michaud G, et al. Gas embolism following bronchoscopic argon plasma coagulation: a case series. Chest 2008; 134:1066.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4405 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-CE19846B1C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24468=[""].join("\n");
var outline_f23_57_24468=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Comparison",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4405|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/19/319\" title=\"picture 1\">",
"      APC probe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8012\" title=\"table 1\">",
"      APC initial settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/6/22635\" title=\"table 2\">",
"      Comparison of modalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_57_24469="Lansoprazole: Patient drug information";
var content_f23_57_24469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lansoprazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     see \"Lansoprazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"     see \"Lansoprazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      First&reg;-Lansoprazole;",
"     </li>",
"     <li>",
"      Prevacid&reg;;",
"     </li>",
"     <li>",
"      Prevacid&reg; 24 HR [OTC];",
"     </li>",
"     <li>",
"      Prevacid&reg; SoluTab&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lansoprazole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lansoprazole;",
"     </li>",
"     <li>",
"      Prevacid&reg;;",
"     </li>",
"     <li>",
"      Prevacid&reg; FasTab;",
"     </li>",
"     <li>",
"      Teva-Lansoprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat NSAID-associated gastric ulcers in patients with a history of ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat ulcers of the swallowing tube (esophagus).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lansoprazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you need Prevacid&reg; 24 HR for more than 14 days in a row, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on 1 tablespoon (15 mL) of applesauce, Ensure&reg; pudding, cottage cheese, yogurt, or strained pears. Do not chew granules.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may mix contents of capsule with 60 mL of apple, orange, or tomato juice. Swallow right away. Do not chew granules.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For patients who have feeding tubes, open the capsule and mix with 3 tablespoons (45 mL) of apple juice. Give in the feeding tube. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10789 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24469=[""].join("\n");
var outline_f23_57_24469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186757\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186758\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023680\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023682\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023681\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023686\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023687\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023689\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023684\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023685\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023690\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023691\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=related_link\">",
"      Lansoprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=related_link\">",
"      Lansoprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_57_24470="Normal cardiac hemodynamics";
var content_f23_57_24470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal cardiac hemodynamics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal cardiac hemodynamics during cardiac catheterization wth a hi-fidelity catheter. One can see the relationships between the surface ECG and simultaneous pressure waves from the aorta (Ao), left ventricle (LV), right atrium (RA), left atrium (LA), and rate of pressure change (dp/dt).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kern, MJ (Ed). Cardiac Catheterization Handbook, 2nd ed, Mosby-Year Book, Inc, St. Louis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24470=[""].join("\n");
var outline_f23_57_24470=null;
var title_f23_57_24471="Chronic cough child";
var content_f23_57_24471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of chronic cough in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 789px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CF: cystic fibrosis; TEF: tracheoesophageal fistula; HRCT: high-resolution computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Shields MD, Bush A, Everard ML, et al. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax 2008; 63 Suppl 3:iii1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24471=[""].join("\n");
var outline_f23_57_24471=null;
var title_f23_57_24472="Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer";
var content_f23_57_24472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Panagiotis A Konstantinopoulos, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Robert E Bristow, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24472/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/57/24472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1480101870\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial cancers of ovarian, fallopian tube, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, these are often combined together and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three histologies under the heading EOC.",
"   </p>",
"   <p>",
"    EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States. Approximately 75 percent of women have stage III (disease that has spread throughout the peritoneal cavity or that involves lymph nodes) or stage IV (disease spread to more distant sites) disease at diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients, EOC is treated surgically and followed by adjuvant platinum and taxane-based chemotherapy. However, neoadjuvant chemotherapy (NACT) prior to definitive surgery is an alternative option in selected patients. This topic will review the rationale and administration of NACT for EOC. Other relevant topics in the treatment of EOC include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"       \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11832?source=see_link\">",
"       \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1480101877\">",
"    <span class=\"h1\">",
"     OBJECTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant chemotherapy (NACT) refers to the administration of systemic therapy before definitive surgery. The goal of NACT is to reduce perioperative morbidity and mortality and increase the likelihood of a complete resection of disease at the time of cytoreductive surgery. Despite the potentially improved surgical outcomes that result from NACT, clinical studies have shown that survival is not improved with NACT compared to standard surgery followed by adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NACT permits the assessment of the effectiveness of chemotherapy prior to surgery, which may help to inform subsequent treatment. Patients who respond well to neoadjuvant therapy are ideal candidates for cytoreductive surgery, while patients who respond poorly or progress on NACT are not likely to benefit from surgical cytoreduction because their disease has proven to be chemotherapy resistant, placing them at high risk for recurrence despite surgery. (See",
"    <a class=\"local\" href=\"#H107813345\">",
"     'Treatment of patients who progress on NACT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282420859\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on which patients with advanced epithelial ovarian cancer (EOC) should be offered neoadjuvant chemotherapy (NACT) (versus primary debulking surgery). We prefer NACT for patients with EOC who are poor operative candidates because of medical comorbidities or a poor performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ). In addition, we offer NACT to women with advanced EOC (eg, stage IIIC or IV) with clinically apparent unresectable disease who are unlikely to become complete or optimally cytoreduced (ie, no residual cancer or &lt;10 mm of residual disease at the end of surgery, respectively) if taken to the operating room at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H282421114\">",
"     'Defining unresectable disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lack of consensus on who are candidates for NACT was reflected at the fourth Gynecologic Cancer InterGroup (GCIG) consensus conference [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/5\">",
"     5",
"    </a>",
"    ]. While the majority of attendees felt that NACT was a standard option for all patients with advanced EOC, others felt that NACT should be offered to a more clearly defined subgroup of women in whom upfront surgery is contraindicated (eg, due to medical comorbidities or poor performance status) or those with imaging detected evidence of tumor dissemination that suggests complete cytoreduction is not possible. In addition, while 82 percent of Society of Gynecologic Oncologist members did not feel there was evidence to justify the administration of NACT in EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/6\">",
"     6",
"    </a>",
"    ], 70 percent of European Society of Gynecological Oncology (ESGO) members felt the evidence was sufficient to recommend NACT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282421087\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision on whether to proceed with neoadjuvant chemotherapy (NACT) is based on the clinical status of the patient and whether or not disease is resectable at the time of presentation. Therefore, all patients require clinical staging. At our institution, this requires baseline imaging (eg, computed tomography of the chest, abdomen, and pelvis) to determine if the disease is resectable or not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282421114\">",
"    <span class=\"h2\">",
"     Defining unresectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts agree that criteria for unresectability include patients with the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deep infiltration of the small bowel mesentery.",
"     </li>",
"     <li>",
"      Diffuse carcinomatosis involving the stomach",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      large parts of the small or large bowel",
"     </li>",
"     <li>",
"      Infiltration of the duodenum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parts of the pancreas (not limited to the pancreatic tail)",
"     </li>",
"     <li>",
"      Involvement of the large vessels of the hepatoduodenal ligament, celiac trunk or behind the porta hepatis",
"     </li>",
"     <li>",
"      Involvement of the liver parenchyma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282421153\">",
"    <span class=\"h2\">",
"     Role of diagnostic laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is often difficult to preoperatively assess whether women with advanced epithelial ovarian cancer (EOC) can be optimally cytoreduced at the time of primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, we advocate a staged surgical assessment for these patients and perform a diagnostic laparoscopy to further evaluate for resectability. If the surgeon conducting the assessment feels disease is resectable, primary surgery should be performed. If complete resectability is unlikely, NACT can be administered. However, other experts prefer to proceed with NACT only in patients who appear to have unresectable disease based on imaging alone.",
"   </p>",
"   <p>",
"    The importance of resectability is underscored by the prognostic significance of a complete or optimal cytoreduction for patients with advanced EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, complete cytoreduction do not solely depend upon the patient's and tumor's characteristics, but also depend on surgical expertise and an institution's infrastructure. In multidisciplinary cancer centers with advanced expertise in gynecologic oncology, optimal debulking rates in excess of 70 percent have been reported even for patients with bulky stage IIIC disease (ie, patients with evidence of abdominal metastases &ge;20 mm preoperatively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/12\">",
"     12",
"    </a>",
"    ]. We strongly advocate that a gynecologic oncologist be involved in surgical decision making and treatment in these circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12942670\">",
"    <span class=\"h1\">",
"     NACT VERSUS PRIMARY SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For selected patients, neoadjuvant chemotherapy (NACT) improves perioperative outcomes and the likelihood of an optimal cytoreduction at surgery compared to primary surgery. The impact of NACT compared to primary surgical cytoreduction was shown in a study involving 6844 women identified in the Surveillance, Epidemiology and End-Results (SEER) database linked to Medicare claims [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared to primary surgery, neoadjuvant chemotherapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly fewer ostomies placed (8 versus 19 percent), less small bowel resections (4 versus 6 percent), and less large bowel resections (11 versus 21 percent)",
"     </li>",
"     <li>",
"      A significant reduction in postoperative complications, including infection (18 versus 11 percent), gastrointestinal complications (35 versus 29 percent), and pulmonary problems (11 versus 4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the benefits of NACT on perioperative outcomes and on the likelihood of a complete cytoreduction, there is no apparent benefit in survival outcomes from NACT does not improve survival outcomes. The following studies illustrate this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2084700402\">",
"    <span class=\"h2\">",
"     EORTC 55971 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Organization for the Research and Treatment of Cancer (EORTC) 55971 trial enrolled 670 women with stage",
"    <span class=\"nowrap\">",
"     IIIC/IV",
"    </span>",
"    epithelial ovarian cancer (EOC) who were randomly assigned to either primary debulking surgery (PDS) followed by six cycles of platinum-based chemotherapy or to NACT with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    &nbsp;and&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    &nbsp;for three cycles followed by interval surgical cytoreduction and adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/1\">",
"     1",
"    </a>",
"    ]. Compared to PDS, NACT resulted in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower rate of complications as compared to initial surgery, including fewer postoperative deaths (0.7 versus 2.5 percent, respectively), infections (2 versus 8 percent), grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      hemorrhage (4 versus 7 percent), and thrombotic events (0 versus 2.6 percent).",
"     </li>",
"     <li>",
"      A higher rate of optimal cytoreduction (defined as &lt;10 mm of residual disease at the end of surgery) (81 versus 42 percent).",
"     </li>",
"     <li>",
"      No difference in median progression free survival (PFS, 12 months in each arm; hazard ratio [HR] 1.01, 95% CI 0.86-1.17) or overall survival (OS, 29 versus 30 months, HR 0.98, 95% CI 0.82-1.18). However, patients treated with primary surgery experienced a statistically nonsignificant improvement in overall survival (OS) compared to those who underwent NACT if there was no residual disease at the time of surgery (45 versus 38 months, respectively) or if there was microscopic residual disease only (ie, to less than 10 mm residual disease, 32 versus 27 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial highlighted potential risks associated with NACT, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease progression &mdash; Approximately 10 percent of those patients who started NACT did not undergo interval surgical cytoreduction, likely due to early disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diagnostic imprecision &mdash; For patients undergoing neoadjuvant chemotherapy, the diagnosis of epithelial ovarian cancer is based on core biopsy or cytologic evaluation of specimens obtained commonly from a peritoneal implant or from pleural or ascitic fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/14\">",
"       14",
"      </a>",
"      ]. As a result, some patients may be wrongly diagnosed as having EOC and subsequently subjected to incorrect chemotherapy and unnecessary surgery. Approximately three percent of patients (n=18) treated on this study had their diagnosis changed at the time of surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study has also been criticized for use of a wide variety of chemotherapy regimens (only 78 and 88 percent of patients in the primary surgery and interval debulking cohorts received platinum and taxane-based chemotherapy, respectively), potential patient selection bias whereby only the",
"    <span class=\"nowrap\">",
"     sickest/most",
"    </span>",
"    medically infirm or the most advanced stage",
"    <span class=\"nowrap\">",
"     IIIC/IV",
"    </span>",
"    disease patients were enrolled, and the heterogeneity in surgical outcomes observed (eg, low rates of complete surgical cytoreduction) in different countries. In addition, the rate of optimal cytoreduction in the cohort undergoing primary surgery was only 42 percent (with less than half successfully cytoreduced to no residual disease), suggesting that maximal surgical effort was not uniformly attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2084700487\">",
"    <span class=\"h2\">",
"     Other trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the EORTC study discussed above, smaller studies have reported on the outcomes of primary surgery versus NACT. These are reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a phase III study from India, 139 patients with stage IIIC or IV EOC were randomly assigned primary surgery or NACT (with interval surgical cytoreduction) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Compared to primary surgery, NACT resulted in a higher rate of optimal cytoreduction (85 versus 23 percent). Furthermore, NACT resulted in shorter inpatient admission days (8 versus 12 days), infection rates (1.4 versus 13 percent), and lower operative mortality (1 versus 6 percent), compared to primary surgical resection. However, there was no difference in progression free or overall survival between the two arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two other randomized studies of neoadjuvant chemotherapy versus primary debulking surgery have completed enrollment. The CHemotherapy OR Upfront Surgery (CHORUS) trial is being conducted in the United Kingdom and has similar design as the EORTC 55971 trial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, the Japanese Clinical Oncology Group (JCOG) 0602 trial compares primary surgical cytoreduction followed by eight cycles of chemotherapy to four cycles of neoadjuvant chemotherapy followed by interval debulking surgery plus additional four cycles of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/20\">",
"       20",
"      </a>",
"      ]. Results of these trials are anticipated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122466\">",
"    <span class=\"h1\">",
"     CHOICE OF REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who will undergo neoadjuvant chemotherapy (NACT), we prefer the intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . This is based on the activity of this combination in the adjuvant treatment of epithelial ovarian cancer (EOC). Dosing and administration of carboplatin and paclitaxel is similar to their use in the adjuvant setting and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842535#H250842535\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Platinum and taxane combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H295902445\">",
"    <span class=\"h1\">",
"     TREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no formal guidelines regarding the ideal assessment strategy for women receiving neoadjuvant chemotherapy (NACT), in our practice we perform serial evaluations, which consist of an interim history and physical examination, complete blood count, serum chemistries (including liver and renal function tests), and CA-125 measurement prior to the start of each cycle. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H295902883\">",
"    <span class=\"h2\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We assess for treatment response with repeat CA-125 measurement and CT after three cycles of neoadjuvant chemotherapy. All patients are also seen by an experienced gynecologic oncology surgeon in order to determine whether to proceed with surgery. We proceed with surgical cytoreduction in patients who do not progress during neoadjuvant chemotherapy and in whom there is a chance of resecting all residual disease or achieving an optimal cytoreduction.",
"   </p>",
"   <p>",
"    Tumor response is typically assessed with Response Evaluation Criteria in Solid Tumors (RECIST) (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"     table 2",
"    </a>",
"    ) and CA-125 measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/21\">",
"     21",
"    </a>",
"    ]. Several studies have attempted to determine the likelihood of optimal surgical cytoreduction following neoadjuvant chemotherapy using clinical parameters, but these have not been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An algorithm that incorporates laparoscopic examination (to identify presence of disease in the bladder peritoneum and the liver surface) and computed tomography has been developed and has 86 percent sensitivity and 99 percent specificity in predicting optimal cytoreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/24\">",
"     24",
"    </a>",
"    ]. However, until these data are further validated, we do not recommend its use in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122616\">",
"    <span class=\"h1\">",
"     DEFINITIVE SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive surgical cytoreduction after neoadjuvant chemotherapy should be attempted when there is a reasonable chance of resecting macroscopic tumor (preferred goal) or at least of achieving an optimal cytoreduction (ie, &lt;10 mm residual disease), preferably gauged by a surgeon with training in gynecologic oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. Surgical cytoreduction should be offered only to women who do not show evidence of disease progression on neoadjuvant chemotherapy (NACT). The surgical approach following NACT is similar to that for women who undergo a primary surgical procedure and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who experience disease progression on NACT should not proceed with surgical cytoreduction. The approach to these patients is discussed below. (See",
"    <a class=\"local\" href=\"#H107813345\">",
"     'Treatment of patients who progress on NACT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122653\">",
"    <span class=\"h2\">",
"     Timing of interval surgical cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal number of NACT cycles that should be administered prior to surgical cytoreduction is not known. Most clinicians evaluate and proceed with interval debulking surgery (IDS, in women who have a response or at least stable disease) after three cycles, as was done in the randomized trial conducted by the EORTC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/1\">",
"     1",
"    </a>",
"    ]. However, other studies have used between four and six cycles prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/20,26-28\">",
"     20,26-28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4122673\">",
"    <span class=\"h1\">",
"     ADJUVANT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women treated with neoadjuvant chemotherapy (NACT), there is no consensus in the best treatment approach following interval debulking surgery. We proceed with further treatment with IV&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    &nbsp;and&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    &nbsp;for at least three cycles, which was done in the European Organization for the Research and Treatment of Cancer (EORTC) study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12942670\">",
"     'NACT versus primary surgery'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H295902688\">",
"    <span class=\"h2\">",
"     Role of intraperitoneal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not administer intraperitoneal (IP) treatment following an interval debulking surgery in women who received NACT. Although three randomized controlled phase III studies have shown the superiority of adjuvant intraperitoneal (IP) chemotherapy over intravenous (IV) chemotherapy in patients with stage III optimally debulked (&le;10 mm residual disease) epithelial ovarian cancer (EOC) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], there are limited data to inform the benefits and risks of IP treatment in women who received neoadjuvant chemotherapy (NACT), which are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Southwest Oncology Group performed a phase II trial involving 26 women with stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      EOC who received three cycles of NACT with IV&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      &nbsp;and&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      followed by an optimal surgical cytoreduction and adjuvant",
"      <span class=\"nowrap\">",
"       IV/IP",
"      </span>",
"      treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/32\">",
"       32",
"      </a>",
"      ]. The following results were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Only 18 patients (69 percent) completed all of the planned treatment.",
"     </li>",
"     <li>",
"      Of the 26 patients who received adjuvant",
"      <span class=\"nowrap\">",
"       IP/IV",
"      </span>",
"      chemotherapy, 11 developed grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      neutropenia as the most frequent toxicity.",
"     </li>",
"     <li>",
"      Median progression free and overall survival was 29 and 34 months, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a separate retrospective study of patients who received IP chemotherapy after primary surgical therapy versus those who received IP chemotherapy after NACT and interval debulking surgery, there was no significant difference between the two groups in the need for dose reduction or delays, use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      on day 8, neurologic, gastrointestinal, or metabolic toxicities, and IP port complications [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/33\">",
"       33",
"      </a>",
"      ]. In addition, there was no significant difference in either mean progression-free survival (18 versus 14 months, respectively) or mean overall survival (69 versus 38 months) between these two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24472/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that IP chemotherapy after NACT is feasible, although whether there is a survival advantage to adjuvant IP therapy following NACT is not clear. Therefore, adjuvant IP therapy in this population should only be used in the context of a clinical trial. Further discussion on the role of IP therapy for EOC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842013#H250842013\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Intraperitoneal chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/537?source=see_link\">",
"     \"Intraperitoneal chemotherapy for treatment of ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107813345\">",
"    <span class=\"h1\">",
"     TREATMENT OF PATIENTS WHO PROGRESS ON NACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop progressive disease during neoadjuvant chemotherapy (NACT) should not undergo surgical cytoreduction. It is highly unlikely that these patients (who were not candidates for a complete cytoreduction at presentation) will be candidates for an optimal cytoreduction if there has been evidence of progression on NACT. In addition, disease progression on NACT is a sign of chemoresistant disease, which places these women at high risk for recurrence regardless of surgical cytoreduction. Therefore, these patients should be spared a potentially morbid operation of unclear survival benefit. Instead, we prefer to treat these patients with medical therapy similar to the treatment of women with platinum-resistant EOC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1480102004\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with epithelial ovarian cancer (EOC) who are poor operative candidates because of a coexisting condition or poor performance status that precludes performance of cytoreductive surgery, we suggest neoadjuvant chemotherapy (NACT) rather than upfront surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This includes women who meet any of the following criteria (see",
"      <a class=\"local\" href=\"#H282421114\">",
"       'Defining unresectable disease'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diffuse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deep infiltration of the root of the small bowel mesentery",
"     </li>",
"     <li>",
"      Diffuse carcinomatosis involving the stomach",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      large parts of the small or large bowel",
"     </li>",
"     <li>",
"      Infiltration of the duodenum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parts of the pancreas (not limited to the pancreatic tail)",
"     </li>",
"     <li>",
"      Involvement of the large vessels of the hepatoduodenal ligament, celiac trunk or behind the porta hepatis",
"     </li>",
"     <li>",
"      Involvement of the liver parenchyma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with stage III or IV EOC in whom it is not clear if complete cytoreduction is possible, we suggest a diagnostic laparotomy to determine resectability rather than proceeding with NACT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H282421153\">",
"       'Role of diagnostic laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who will undergo NACT, we suggest intravenous platinum-based chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preference is to administer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      given the activity of this combination in the adjuvant setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842535#H250842535\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Platinum and taxane combination therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although there are no formal guidelines regarding the ideal assessment strategy for women receiving NACT, in our practice we perform serial evaluations, which consist of an interim history and physical examination, complete blood count, serum chemistries (including liver and renal function tests), and CA-125 measurement prior to the start of each cycle. (See",
"      <a class=\"local\" href=\"#H4122466\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We evaluate for treatment response after three NACT cycles. We proceed with a surgical cytoreduction in patients in whom there is a chance of resecting all residual disease (or achieving an optimal cytoreduction), preferably gaged by an experienced gynecologic oncology surgeon. (See",
"      <a class=\"local\" href=\"#H4122616\">",
"       'Definitive surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following surgery, we recommend adjuvant platinum-based chemotherapy rather than no further treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest intravenous&nbsp;chemotherapy rather than a regimen that incorporates intraperitoneal therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preference is to administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      &nbsp;and&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      for at least three cycles. (See",
"      <a class=\"local\" href=\"#H4122673\">",
"       'Adjuvant treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who experience disease progression during NACT, we do not proceed with surgical cytoreduction. These patients should be offered medical therapy similar to the treatment of women with platinum-resistant EOC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/1\">",
"      Vergote I, Trop&eacute; CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/2\">",
"      Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2012; 8:CD005343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/3\">",
"      Vergote I, Trop&eacute; CG, Amant F, et al. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol 2011; 29:4076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/4\">",
"      Vergote I, du Bois A, Amant F, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol 2013; 128:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/5\">",
"      Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/6\">",
"      Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010; 119:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/7\">",
"      Cornelis S, Van Calster B, Amant F, et al. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer 2012; 22:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/8\">",
"      Salani R, Bristow RE. Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol 2012; 55:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/9\">",
"      Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/10\">",
"      Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006; 103:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/11\">",
"      du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 115:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/12\">",
"      Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/13\">",
"      Thrall MM, Gray HJ, Symons RG, et al. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol 2011; 123:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/14\">",
"      Konstantinopoulos PA, Awtrey CS. Management of ovarian cancer: a 75-year-old woman who has completed treatment. JAMA 2012; 307:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/15\">",
"      Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol 2011; 29:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/16\">",
"      Vergote I, Leunen K, Amant F. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges? Gynecol Oncol 2012; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/17\">",
"      Hoskins PJ. Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking? Curr Opin Oncol 2011; 23:501.",
"     </a>",
"    </li>",
"    <li>",
"     Kumar L, Hariprasad R, Kumar S. Upfront surgery vs neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma (EOC): a randomized study. IGCS. Prague; 2010.",
"    </li>",
"    <li>",
"     file://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/20\">",
"      Onda T, Matsumoto K, Shibata T, et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol 2008; 38:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/21\">",
"      Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/22\">",
"      Rodriguez N, Rauh-Hain JA, Shoni M, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2012; 125:362.",
"     </a>",
"    </li>",
"    <li>",
"     de Jong D, Dodge JE, Freedman O, et al. Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. J Clin Oncol 2009; 27:15s: abstr 5512.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/24\">",
"      Bland AE, Everett EN, Pastore LM, et al. Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy. Int J Gynecol Cancer 2008; 18:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/25\">",
"      Schwartz PE. Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer. Curr Oncol Rep 2009; 11:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/26\">",
"      Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999; 72:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/27\">",
"      Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007; 105:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/28\">",
"      Schwartz PE. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology (Williston Park) 2008; 22:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/29\">",
"      Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/30\">",
"      Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/31\">",
"      Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/32\">",
"      Tiersten AD, Liu PY, Smith HO, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol 2009; 112:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/33\">",
"      Le T, Latifah H, Jolicoeur L, et al. Comparative study of grade 3/4 toxicity associated with intraperitoneal chemotherapy administered after primary versus interval surgical debulking in ovarian cancer. Int J Gynecol Cancer 2011; 21:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24472/abstract/34\">",
"      Le T, Latifah H, Jolicoeur L, et al. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy? Gynecol Oncol 2011; 121:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86318 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24472=[""].join("\n");
var outline_f23_57_24472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1480102004\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480101870\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480101877\">",
"      OBJECTIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282420859\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282421087\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282421114\">",
"      Defining unresectable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282421153\">",
"      Role of diagnostic laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12942670\">",
"      NACT VERSUS PRIMARY SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2084700402\">",
"      EORTC 55971 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2084700487\">",
"      Other trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4122466\">",
"      CHOICE OF REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295902445\">",
"      TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H295902883\">",
"      Response assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4122616\">",
"      DEFINITIVE SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4122653\">",
"      Timing of interval surgical cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4122673\">",
"      ADJUVANT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H295902688\">",
"      Role of intraperitoneal therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107813345\">",
"      TREATMENT OF PATIENTS WHO PROGRESS ON NACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480102004\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/86318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/86318|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42764\" title=\"table 2\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/537?source=related_link\">",
"      Intraperitoneal chemotherapy for treatment of ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11832?source=related_link\">",
"      The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_57_24473="Beckwith-Wiedemann syndrome";
var content_f23_57_24473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beckwith-Wiedemann syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Brian Chung Hon-Yin, MD, FCCMG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Cheryl Shuman, MS, CGC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Sanaa Choufani, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Rosanna Weksberg, MD, PhD, FRCPC, FCCMG, FACMG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24473/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/57/24473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22939433\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beckwith-Wiedemann syndrome (BWS, MIM #130650) is a pediatric overgrowth disorder involving a predisposition to tumor development [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical presentation is highly variable, and some cases lack the characteristic features originally described by Beckwith and Wiedemann [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. BWS also exhibits etiologic molecular heterogeneity and some molecular alterations correlate with specific phenotypic features of BWS.",
"   </p>",
"   <p>",
"    The epidemiology, genetics, pathogenesis, clinical manifestation, diagnosis, management, and prognosis of BWS are reviewed in this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618222\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;BWS is a panethnic disorder with an estimated population incidence of 1 in 13,700 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/4\">",
"     4",
"    </a>",
"    ]. This figure most likely represents an underestimate, because milder phenotypes may not be ascertained. The incidence is equal in males and females, with the notable exception of an increased incidence in female monozygotic twins versus male monozygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/5\">",
"     5",
"    </a>",
"    ]. BWS usually occurs sporadically (85 percent), but familial transmission occurs in approximately 15 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1618409\">",
"    <span class=\"h1\">",
"     GENETICS AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, both the maternally and paternally inherited allele of each autosomal gene pair is expressed. Less than 100 genes across the genome are imprinted and expressed monoallelically in a parent of origin specific manner (",
"    <a class=\"graphic graphic_figure graphicRef54712 \" href=\"UTD.htm?28/36/29248\">",
"     figure 1",
"    </a>",
"    ). Genomic imprinting is regulated by epigenetic modifications. These modifications are extrinsic to changes in primary nucleotide sequence and",
"    <strong>",
"    </strong>",
"    include DNA methylation, histone modification, and noncoding RNAs. Imprinting centers (ICs), also called imprinting control elements or differentially methylated regions (DMRs), are regions of DNA that regulate the expression of imprinted genes in cis (on the same chromosome) over large distances and demonstrate differential methylation of",
"    <strong>",
"    </strong>",
"    the parental alleles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of Mendelian inheritance\", section on 'Parent-of-origin effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deregulation of imprinted gene expression in the chromosome 11p15.5 region can result in the BWS phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The BWS critical genes in that region include insulin-like growth factor 2 (IGF2), H19, cyclin-dependent kinase inhibitor 1C (CDKN1C), potassium channel voltage-gated KQT-like subfamily member 1 (KCNQ1), and KCNQ1-overlapping transcript 1 (KCNQ1OT1, or long QT intronic transcript 1, LIT1). A chromosome 11p15 molecular alteration is identified in only about 80 percent of individuals with BWS. This may be due, in part, to somatic mosaicism for some of the molecular alterations.",
"   </p>",
"   <p>",
"    Other genomic loci are probably also involved in the etiology of BWS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/9\">",
"     9",
"    </a>",
"    ]. Molecular studies have demonstrated two genes, NALP2 on chromosome 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/10\">",
"     10",
"    </a>",
"    ] and ZFP57 on chromosome 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/11\">",
"     11",
"    </a>",
"    ] that can modulate imprinting in the chromosome 11p15.5 region. In addition, an infant with features of BWS was found to have a large chromosome 7 deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/12\">",
"     12",
"    </a>",
"    ]. This deletion included the growth factor receptor-bound protein 10 gene (GRB10), an imprinted gene that inhibits the growth-promoting activities of insulin and insulin-like growth factors 1 and 2 by binding to the receptors for these molecules (insulin receptor and insulin-like growth factor 1 receptor). Chromosome 18q deletions were reported in individuals with some features of BWS and developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Domain 1 of the chromosome 11p15.5 region is the telomeric imprinted domain that contains the imprinted genes H19 and IGF2. H19 is a non-translated RNA that may function as a tumor suppressor gene. IGF2 is a potent fetal growth factor. IGF2 overexpression is likely to be a key determinant in the development of BWS. H19 and IGF2 are reciprocally expressed imprinted genes, with H19 maternally expressed and IGF2 paternally expressed. The expression of genes within this domain is regulated by an imprinting center upstream of H19 called IC1 (imprinting center 1). IC1 is normally methylated on the paternal allele and unmethylated on the maternal allele. Regulation of transcription is accomplished by binding of the zinc-finger insulator protein CTCF to its consensus sequence within IC1. CTCF only binds to the unmethylated sequence (maternal allele) and interferes with downstream enhancers interacting with the IGF2 promoters [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Domain 2 is the centromeric imprinted domain that contains the imprinted genes CDKN1C, KCNQ1, and KCNQ1OT1. Regulation of this domain is controlled by an imprinting center, IC2, located in intron 10 of the KCNQ1 gene. IC2 is a differentially methylated region [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/15\">",
"     15",
"    </a>",
"    ] that contains the promoter for KCNQ1OT1 &mdash; a noncoding RNA with regulatory function. Loss of methylation at IC2 results in biallelic expression of the normally paternally expressed KCNQ1OT1. Individuals with BWS and loss of methylation at IC2 have reduced CDKN1C expression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/16\">",
"     16",
"    </a>",
"    ]. Loss of methylation at IC2 is reported in association with loss of methylation at multiple imprinted regions across the genome in some BWS cases.",
"   </p>",
"   <p>",
"    A number of different mechanisms can lead to BWS via either epigenetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic alterations in the chromosome 11p15.5 imprinted domains. These modifications change the relative contributions",
"    <strong>",
"    </strong>",
"    of parental alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] and include parent of origin specific duplications,",
"    <span class=\"nowrap\">",
"     translocations/inversions,",
"    </span>",
"    microdeletions, microduplications, DNA methylation changes at IC1 or IC2, and uniparental disomy (UPD). UPD refers to the presence of two chromosomal regions from one parent and none from the other.",
"   </p>",
"   <p>",
"    The following molecular alterations can be detected in individuals with BWS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/8,17\">",
"     8,17",
"    </a>",
"    ] (the percentage of cases with each type of alteration is quoted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loss of methylation at IC2 (50 percent)",
"     </li>",
"     <li>",
"      Paternal uniparental disomy 11 (20 percent)",
"     </li>",
"     <li>",
"      Gain of methylation at IC1 (5 percent)",
"     </li>",
"     <li>",
"      Mutation of CDKN1C (5 percent in sporadic cases)",
"     </li>",
"     <li>",
"      Duplication, inversion, or translocation involving the p15.5 band of chromosome 11 (rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methylation changes, usually in domain 1, are associated with genomic alterations (microdeletions or microduplications) involving the imprinting centers in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Genomic alterations with or without changes in methylation are important because of their heritability. Epigenetic alterations that involve both IC1 and IC2 generally indicate paternal UPD for a chromosomal segment including the 11p15.5 region [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    Segmental UPD",
"    <strong>",
"    </strong>",
"    of chromosome 11",
"    <strong>",
"    </strong>",
"    generally",
"    <strong>",
"    </strong>",
"    arises from a post-zygotic somatic recombination event and therefore has a mosaic distribution in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130269\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark features of BWS include omphalocele (exomphalos), macroglossia, and macrosomia (gigantism) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; however, there is significant clinical heterogeneity. Incidence figures for the specific individual clinical findings in BWS vary widely in published reports, perhaps representing ascertainment biases. (See",
"    <a class=\"local\" href=\"#H1619903\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Findings associated with BWS include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Macrosomia (traditionally defined as height and weight &gt;97th percentile)",
"     </li>",
"     <li>",
"      Hemihyperplasia (asymmetric overgrowth of one or more regions of the body due to an abnormality of cell proliferation, ie increased cell number) (",
"      <a class=\"graphic graphic_picture graphicRef66409 \" href=\"UTD.htm?42/35/43571\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Macroglossia (",
"      <a class=\"graphic graphic_picture graphicRef80654 \" href=\"UTD.htm?10/19/10545\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Omphalocele/umbilical",
"      </span>",
"      <span class=\"nowrap\">",
"       hernia/diastasis",
"      </span>",
"      recti (",
"      <a class=\"graphic graphic_figure graphicRef69049 \" href=\"UTD.htm?26/51/27455\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81489 \" href=\"UTD.htm?16/60/17359\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anterior linear ear lobe",
"      <span class=\"nowrap\">",
"       creases/posterior",
"      </span>",
"      helical ear pits (",
"      <a class=\"graphic graphic_picture graphicRef77586 \" href=\"UTD.htm?4/16/4354\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Visceromegaly involving one or more intra-abdominal organs including liver, spleen, kidneys, adrenal glands, and pancreas",
"     </li>",
"     <li>",
"      Embryonal tumors (eg, Wilms tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma) in childhood (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link\">",
"       \"Presentation, diagnosis, and staging of Wilms tumor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link\">",
"       \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cytomegaly of the fetal adrenal cortex when present is pathognomonic",
"     </li>",
"     <li>",
"      Renal abnormalities including structural anomalies, nephromegaly, nephrocalcinosis, later development of medullary sponge kidney",
"     </li>",
"     <li>",
"      Cleft palate (rare)",
"     </li>",
"     <li>",
"      Neonatal hypoglycemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"       \"Neonatal hypoglycemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Facial nevus flammeus, other vascular malformations (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link\">",
"       \"Vascular lesions in the newborn\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Characteristic facies, including midface hypoplasia and infraorbital creases (",
"      <a class=\"graphic graphic_picture graphicRef80654 \" href=\"UTD.htm?10/19/10545\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Cardiomegaly/structural",
"      </span>",
"      cardiac anomalies; cardiomyopathy (rare)",
"     </li>",
"     <li>",
"      Advanced bone age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other features that are part of the phenotype are discussed in greater detail in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351639\">",
"    <span class=\"h2\">",
"     Prenatal and perinatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common features of BWS observed prenatally are macrosomia (90 percent) and polyhydramnios (50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Fifty percent of affected infants are born preterm. The umbilical cord is long and the placenta averages almost twice the normal weight for gestational age. Manifestations of BWS have been observed in about one-third of",
"    <span class=\"nowrap\">",
"     fetuses/liveborn",
"    </span>",
"    infants from pregnancies complicated by placental mesenchymal dysplasia, which is distinctive cystic placental phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351646\">",
"    <span class=\"h2\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macroglossia and macrosomia are generally present at birth, although postnatal onset of each of these features is sometimes observed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Adult height typically remains at the upper range of normal despite rapid growth in early childhood. The growth rate usually slows around age seven to eight years of age.",
"   </p>",
"   <p>",
"    Hemihyperplasia (also called hemihypertrophy), if present, is generally appreciated at birth, but may become more or less evident as the child grows. Hemihyperplasia may affect segmental regions of the body",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    selected organs and tissues. When several segments are involved, hemihyperplasia may be limited to one side of the body (ipsilateral) or involve opposite sides of the body (contralateral) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351653\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal hypoglycemia is well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/4,29\">",
"     4,29",
"    </a>",
"    ]. It poses a significant risk for developmental sequelae if severe and undetected or untreated. In those pregnancies deemed at increased risk for BWS either because of a positive family history or detection of fetal omphalocele on ultrasound, the newborn should be evaluated for hypoglycemia. Most cases of hypoglycemia are mild and transient, however, rarely, hypoglycemia can persist and be refractory to treatment. Delayed onset of hypoglycemia (ie, beyond the first two weeks of life) is also rarely observed.",
"   </p>",
"   <p>",
"    Other less common",
"    <span class=\"nowrap\">",
"     endocrine/metabolic/hematologic",
"    </span>",
"    findings include hypothyroidism,",
"    <span class=\"nowrap\">",
"     hyperlipidemia/hypercholesterolemia,",
"    </span>",
"    and polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351660\">",
"    <span class=\"h2\">",
"     Structural anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior abdominal wall defects, including omphalocele, umbilical hernia, and diastasis recti, are common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much of the information regarding cardiovascular problems in BWS is anecdotal. Cardiomegaly is commonly detected in infancy if a chest X-ray is done, but this typically resolves without treatment. There are rare reports of cardiomyopathy.",
"   </p>",
"   <p>",
"    Renal anomalies include medullary dysplasia, duplicated collecting system, nephrocalcinosis, medullary sponge kidney, cystic changes, diverticuli, and nephromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Hypercalciuria can be found in children with BWS even in the absence of renal abnormalities visualized by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare cases of posterior fossa brain abnormalities have been reported in patients with BWS who have involvement of the centromeric imprinted domain (domain 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1618409\">",
"     'Genetics and pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1351674\">",
"     'Development'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351667\">",
"    <span class=\"h2\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with BWS have an increased risk of mortality associated with neoplasia, particularly Wilms tumor and hepatoblastoma, but also neuroblastoma, adrenocortical carcinoma, and rhabdomyosarcoma as well as a wide variety of other tumors, both malignant and benign [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/35\">",
"     35",
"    </a>",
"    ]. The estimated risk for tumor development in children with BWS is 7.5 percent, with a range of risks estimated between 4 percent and 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/4,23,24,35-40\">",
"     4,23,24,35-40",
"    </a>",
"    ]. This increased risk for neoplasia is concentrated in the first eight years of life. Tumor development is uncommon in affected individuals older than age eight years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351674\">",
"    <span class=\"h2\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development is usually normal in children with BWS unless there is a chromosome abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/34,41\">",
"     34,41",
"    </a>",
"    ] or a history of hypoxia or significant, untreated hypoglycemia. Neurobehavioral issues, such as autism spectrum disorder, are reported with increased frequency in children with BWS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/42\">",
"     42",
"    </a>",
"    ]; however, these cases were ascertained by parental report only. Additional studies, including formal neurodevelopmental assessments, are needed to assess the frequencies of these issues in BWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887409\">",
"    <span class=\"h1\">",
"     PHENOTYPE-(EPI)GENOTYPE CORRELATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of genetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epigenetic alterations in growth regulatory genes on chromosome 11p15.5 are associated with specific phenotype-(epi)genotype correlations and different inheritance risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887416\">",
"    <span class=\"h2\">",
"     Tumor development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with UPD of 11p15.5 or gain of methylation at the H19 imprinting center (IC1), carry the highest risk of developing Wilms tumor or hepatoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/6,43-48\">",
"     6,43-48",
"    </a>",
"    ]. Those with loss of maternal methylation at IC2 also carry a moderately increased tumor risk (but not for Wilms tumor). Individuals with mutations in CDKN1C appear to have the lowest risk of tumor formation, with only a small number of cases of neuroblastoma reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887423\">",
"    <span class=\"h2\">",
"     Hemihyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic mosaicism for UPD of chromosome 11p15.5 resulting in methylation alterations at IC2 or IC1 is associated with hemihyperplasia (also called hemihypertrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/7,49\">",
"     7,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887430\">",
"    <span class=\"h2\">",
"     Omphalocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;IC2 alterations and CDKN1C mutations are associated with omphalocele [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887437\">",
"    <span class=\"h2\">",
"     Developmental delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental delay is associated with cytogenetically detectable duplications involving the paternal copy of chromosome 11p15.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/7,41,51\">",
"     7,41,51",
"    </a>",
"    ], although it may also be due to a significant episode of neonatal hypoglycemia or result as a consequence of prematurity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887444\">",
"    <span class=\"h2\">",
"     Severe BWS phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of severe BWS have been reported in association with very high levels of somatic mosaicism of paternal UPD for chromosome 11p15.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887451\">",
"    <span class=\"h2\">",
"     Positive family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most familial cases of BWS are due to mutations in CDKN1C or microdeletions of IC1 or, very rarely, IC2 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/7,18,20,21,54-57\">",
"     7,18,20,21,54-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887458\">",
"    <span class=\"h2\">",
"     Female monozygotic twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a larger than expected number of female monozygotic twins discordant for BWS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/5\">",
"     5",
"    </a>",
"    ]. The affected females usually demonstrate loss of methylation at IC2. In contrast, the less frequently observed male monozygotic twins show a broad spectrum of BWS-associated molecular alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887465\">",
"    <span class=\"h2\">",
"     Infertility/assisted reproductive technology (ART)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART appears to be associated with an increased risk of BWS cases due to loss of methylation at IC2 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/49,58-60\">",
"     49,58-60",
"    </a>",
"    ]. It is not clear what specific aspects of infertility or its treatment drive this association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1619903\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consensus diagnostic criteria exist for BWS, although the presence of a subset of characteristic findings are used to confer a clinical diagnosis. The phenotype of BWS is highly variable and may include as few as two of the recognized clinical features. Approximately 15 percent of cases of BWS are familial. Thus, targeted questions should be elicited regarding family history, including information about parental status during childhood, since BWS features present in childhood may have normalized over time. In addition, maternal conception history and pregnancy-related findings, such as polyhydramnios, placental mesenchymal dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/25\">",
"     25",
"    </a>",
"    ], and prematurity should be ascertained. (See",
"    <a class=\"local\" href=\"#H130269\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1618222\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Notably, children with mild phenotypes (eg, macroglossia and umbilical hernia) are still at increased risk for tumor development. Thus, there should be a high index of suspicion when evaluating children with minimal clinical features in the BWS phenotypic spectrum, particularly if there is a positive family history (one or more family members with a clinical diagnosis of BWS or a history or features suggestive of BWS). In such cases anticipatory medical management (eg, tumor surveillance) and molecular testing should be considered. (See",
"    <a class=\"local\" href=\"#H22939583\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1619017\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methylation-sensitive multiplex ligation probe analysis (MS-MLPA)",
"    <strong>",
"    </strong>",
"    is the most robust method clinically available for detecting the majority of epigenetic and genetic etiologies associated with BWS. MS-MLPA detects",
"    <span class=\"nowrap\">",
"     microdeletions/microduplications",
"    </span>",
"    and alterations in gene dosage and DNA methylation including uniparental disomy (UPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Somatic mosaicism associated with UPD may lead to weak signals on MS-MLPA. UPD can be confirmed by analysis of short tandem repeats when it is suggested by methylation alterations at both IC1 and IC2. In addition, failure to detect a methylation alteration or UPD in one tissue (usually leukocytes) is not conclusive, especially in cases involving hemihyperplasia. Thus, testing of at least two",
"    <span class=\"nowrap\">",
"     tissues/cell",
"    </span>",
"    populations, for example leukocytes and skin, should be considered.",
"   </p>",
"   <p>",
"    Karyotype analysis will detect the rare de novo and maternally transmitted",
"    <span class=\"nowrap\">",
"     translocations/inversions",
"    </span>",
"    (approximately 1 percent) and paternally derived duplications (approximately 1 percent) of chromosome 11p15.5 associated with BWS.",
"    <span class=\"nowrap\">",
"     Translocations/inversions",
"    </span>",
"    almost always disrupt the gene KCNQ1",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/15\">",
"     15",
"    </a>",
"    ]",
"    <strong>",
"    </strong>",
"    and",
"    <strong>",
"    </strong>",
"    are not usually detectable by MS-MLPA because most do not demonstrate DNA copy number changes or DNA methylation changes.",
"   </p>",
"   <p>",
"    DNA sequencing is required to detect genomic alterations",
"    <strong>",
"    </strong>",
"    in the CDKN1C gene associated with BWS. CDKN1C mutations are seen both sporadically (5 percent of cases) and in autosomal dominant pedigrees modified by preferential parent of origin-specific transmission (40 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887889\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for prenatal testing may include a previous child with BWS or a positive family history of BWS. Prenatal testing may be undertaken by chorionic villus sampling (CVS) or amniocentesis if the cytogenetic or genomic abnormality (eg, microdeletion, CDKN1C mutation) in the affected family member is known. Epigenetic analysis of chromosome 11p15.5 in amniocytes is sufficiently reliable for prenatal diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/62\">",
"     62",
"    </a>",
"    ]. However, analysis of methylation alterations in CVS requires further investigation before this can be offered as a clinical test.",
"   </p>",
"   <p>",
"    Prenatal testing via amniocentesis may also be indicated for suspicious findings detected on fetal ultrasound such as omphalocele, renal enlargement, or macroglossia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/63\">",
"     63",
"    </a>",
"    ]. A follow-up study of apparently isolated fetal omphalocele (ie, no known family history of BWS and no additional findings detected on fetal ultrasound) reported BWS in 20 percent of cases based upon subsequent clinical evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecular testing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/64\">",
"     64",
"    </a>",
"    ]. Thus, molecular testing is suggested in such cases.",
"   </p>",
"   <p>",
"    Prenatal screening is an option if the molecular defect is not known or if invasive prenatal testing is not undertaken. This screening includes measurement of maternal serum alpha fetoprotein (AFP) to detect abdominal wall defects and ultrasound evaluation for assessment of growth parameters that may become advanced for gestational age (usually after 24 weeks), abdominal wall defects, organomegaly, renal abnormalities, cleft palate, cardiac anomalies, and macroglossia. Nuchal translucency measurements between 10 to 14 weeks can be informative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/65\">",
"     65",
"    </a>",
"    ] and detailed ultrasound is typically performed at 18 to 20 weeks and again at 25 to 32 weeks gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22939447\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of a newborn with large growth parameters (",
"    <a class=\"graphic graphic_table graphicRef53324 \" href=\"UTD.htm?1/51/1851\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62919 \" href=\"UTD.htm?32/44/33483\">",
"     table 2",
"    </a>",
"    ), macroglossia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoglycemia, should prompt a comprehensive clinical examination followed by relevant investigations. A number of endocrine disorders and overgrowth syndromes should be considered in the differential diagnosis, including maternal diabetes mellitus and congenital hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several genetic syndromes have features in common with BWS, but can be distinguished by genetic testing, ancillary tests (eg, brain imaging, molecular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical testing), and follow-up for the appearance of defining features. The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Simpson-Golabi-Behmel syndrome (type 1 MIM #312870, type 2 MIM #300209)",
"     </li>",
"     <li>",
"      Costello syndrome (MIM #218040)",
"     </li>",
"     <li>",
"      Perlman syndrome (MIM #267000)",
"     </li>",
"     <li>",
"      Sotos syndrome (MIM #117550)",
"     </li>",
"     <li>",
"      Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome, MIM #253200)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For cases involving asymmetry as an isolated finding, it is important to determine if the asymmetry represents overgrowth (hemihyperplasia) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/28,66-68\">",
"     28,66-68",
"    </a>",
"    ] or decreased growth (hemihypoplasia), since the latter is not associated with an increased risk for tumor development. Molecular testing may provide clarification in that hemihypoplasia may be associated with hypomethylation of IC1 as opposed to hemihyperplasia with hypermethylation of IC1 or chromosome 11p15.5 UPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1351646\">",
"     'Growth'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1619017\">",
"     'Genetic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22939583\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22939591\">",
"    <span class=\"h2\">",
"     Evaluation following initial diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following evaluations are advised to establish the extent of disease in an individual diagnosed with BWS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment for airway sufficiency in the presence of macroglossia.",
"     </li>",
"     <li>",
"      Evaluation by a feeding specialist if macroglossia causes significant feeding difficulties.",
"     </li>",
"     <li>",
"      Assessment of neonates for hypoglycemia; evaluation by a pediatric endocrinologist if significant hypoglycemia persists beyond the first few days of life.",
"     </li>",
"     <li>",
"      Abdominal ultrasound examination to assess for organomegaly, structural abnormality, and tumors. A baseline MRI or CT examination of the abdomen to screen for tumors may be considered at the time of diagnosis or later [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comprehensive cardiac evaluation including ECG and echocardiogram prior to any surgical procedures or when a cardiac abnormality is suspected on clinical evaluation.",
"     </li>",
"     <li>",
"      Alpha fetoprotein assay at the time of initial diagnosis to assess for hepatoblastoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22939600\">",
"    <span class=\"h2\">",
"     Treatment of manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following measures are advised for disease manifestations that may appear throughout the course of the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prompt treatment of hypoglycemia to reduce the risk of central nervous system complications. The onset of hypoglycemia is variable, and therefore parents should be informed of the symptoms of hypoglycemia so that they know when to seek appropriate medical attention for their child.",
"     </li>",
"     <li>",
"      Abdominal wall repair soon after birth for omphalocele. This surgery is generally well tolerated.",
"     </li>",
"     <li>",
"      Management of difficulties arising from macroglossia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anticipation of difficulties with endotracheal intubation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary assessment, possibly including sleep study, to address concern regarding potential sleep apnea.",
"     </li>",
"     <li>",
"      Management of feeding difficulties using specialized nipples, such as the longer nipple recommended for babies with cleft palate or, rarely, short-term use of nasogastric tube feedings.",
"     </li>",
"     <li>",
"      Follow-up by a craniofacial team including plastic surgeons, orthodontists, and speech pathologists familiar with the natural history of BWS. Tongue growth slows over time and jaw growth can accelerate to accommodate the enlarged tongue. Some children benefit from tongue reduction surgery; however, surgical reduction typically impacts tongue length not thickness. Residual cosmetic, orthodontic, and speech issues may require further",
"      <span class=\"nowrap\">",
"       assessment/treatment",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consultation with an orthopedic surgeon if hemihyperplasia results in a significant difference in leg length. Surgery may be necessary during early puberty to close the growth plate of the longer leg in order to equalize the final leg lengths.",
"     </li>",
"     <li>",
"      Referral to a craniofacial surgeon if facial hemihyperplasia is significant.",
"     </li>",
"     <li>",
"      Treatment of neoplasia following standard pediatric oncology protocols.",
"     </li>",
"     <li>",
"      Standard interventions, such as infant stimulation programs, occupational and physical therapy, and individualized education programs, for children with developmental delay.",
"     </li>",
"     <li>",
"      Referral of children with structural renal or gastrointestinal tract abnormalities to the relevant specialists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22939609\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor for hypoglycemia in the first few days of life by random blood glucose measurements to detect asymptomatic hypoglycemia and have a higher index of suspicion",
"      <span class=\"nowrap\">",
"       for/awareness",
"      </span>",
"      of clinical signs of hypoglycemia.",
"     </li>",
"     <li>",
"      Screen for developmental issues as part of routine childcare, especially when there is a history of hypoglycemia, prematurity, or evidence of chromosome 11p15.5 duplication.",
"     </li>",
"     <li>",
"      Assess individuals over eight years of age through adolescence with annual or biannual renal ultrasound examination to identify those requiring further",
"      <span class=\"nowrap\">",
"       evaluation/management,",
"      </span>",
"      since nephrocalcinosis and medullary sponge kidney develop at a later age.",
"     </li>",
"     <li>",
"      Consider measurement of urinary",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio annually or biannually, since it may be abnormal in individuals with renal disease who have normal renal findings on ultrasound examination [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Screen for embryonal tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/73\">",
"       73",
"      </a>",
"      ] by:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abdominal ultrasound examination every three months until age eight years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/39,70,74,75\">",
"       39,70,74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measure serum alpha fetoprotein (AFP) concentration every two to three months in the first four years of life for early detection of hepatoblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/74\">",
"       74",
"      </a>",
"      ]. AFP serum concentration may be mildly elevated in children with BWS in the first year of life in the absence of a hepatoblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/76\">",
"       76",
"      </a>",
"      ]. If the AFP is elevated in the absence of a suspicious lesion on imaging, follow-up measurement of serum AFP concentration plus baseline liver function tests four to six weeks later can be used to determine the trend in serum AFP concentrations over time. If a decline in AFP concentration is not seen, it is appropriate to refer to an oncologist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      undertake an exhaustive search for an underlying tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Periodic chest x-ray and urinary VHA (homovanillic acid) and VMA (vanilmandelic acid) assays to screen for neuroblastoma have been suggested, but have not been incorporated into most screening protocols because of their low yield.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consideration should be given to offering tumor surveillance for those cases presenting with a &ldquo;mild&rdquo; phenotype (see",
"    <a class=\"local\" href=\"#H1619903\">",
"     'Diagnosis'",
"    </a>",
"    above). Additionally, tumor surveillance is suggested for the clinically unaffected monozygotic twin of a child with BWS because of the possibility of low level mosaicism and shared fetal circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22939618\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling regarding etiology and recurrence risk (ie, risk of a subsequent affected child) for BWS is most accurate if data from a complete diagnostic evaluation are available, including molecular testing. These data include family history, clinical findings, karyotype, MS-MLPA, and CDKN1C mutation analysis if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=see_link\">",
"     \"Basic principles of genetic counseling for the obstetrical provider\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recurrence risk is low if molecular testing reveals UPD or a methylation alteration in the absence of a transmissible genomic alteration. Information regarding recurrence risk for some of the molecular subtypes remains theoretical rather than definitive, since there are no confirmatory empiric data. This is especially relevant when providing genetic counseling for affected individuals with theoretically low recurrence risk (eg, UPD for chromosome 11p15, methylation alterations at IC2). Molecular testing is typically not indicated for parents or other family members when UPD is found, since these cases arise via post-zygotic somatic recombination. Parental studies are recommended if genomic alterations are found (eg, karyotype abnormalities, CDKN1C mutations, or microduplications or microdeletions of the chromosome 11p15.5 region).",
"   </p>",
"   <p>",
"    Molecular alterations that are associated with significant recurrence risk include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal transmission of chromosome 11p15.5",
"      <span class=\"nowrap\">",
"       translocation/inversions",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maternal transmission of CDKN1C mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chromosome 11p15.5 duplication of paternal origin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      11p15.5",
"      <span class=\"nowrap\">",
"       microdeletion/microduplication",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Molecular testing or chromosome analysis is indicated for both parents and potentially other family members if either a translocation or inversion involving chromosome 11p15.5 or aCDKN1C mutation is found in the proband. The recurrence risk is 50 percent for CDKN1C mutations and for translocations or inversions involving chromosome 11p15.5 if the transmitting parent is the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/55\">",
"     55",
"    </a>",
"    ]. The risk is low if the CDKN1C mutation is found in the father, however, at least one case of BWS and paternal transmission of this mutation has been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/57\">",
"     57",
"    </a>",
"    ]. The recurrence risk for paternally derived duplications is not specifically defined, but is probably significant if the father carries a translocation. Familial transmissions involving microdeletions of IC1 and one case of IC2 have been reported, therefore parental testing is indicated when these alterations are identified [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/20,21,54\">",
"     20,21,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recurrence risk can be estimated empirically in the case of a positive family history in the absence of an abnormal genetic test result. Information incorporated into such estimates includes the sex and potential carrier status of the transmitting parent. All potential etiologies consistent with the positive family history should be considered. The recurrence risk for BWS in cases where there is no identified cause may be as high as 50 percent. Gonadal mosaicism remains a possibility, although it has not been reported to date. It should be considered when parents are not found to carry a transmissible microdeletion or mutation associated with BWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351427\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with BWS are at increased risk for mortality mainly due to complications of prematurity, macroglossia, hypoglycemia, tumors, and, rarely, cardiomyopathy. A previously reported mortality rate of 20 percent may be an overestimate given the recent improvements in syndrome recognition and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/4,24,53\">",
"     4,24,53",
"    </a>",
"    ]. Prognosis is generally favorable after childhood. However, complications for individuals with BWS can occur (eg, renal medullary dysplasia, subfertility in males). Such issues may be associated with specific molecular subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24473/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1887409\">",
"     'Phenotype-(epi)genotype correlations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1620147\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beckwith-Wiedemann syndrome (BWS) is a pediatric overgrowth disorder involving a predisposition to tumor development. (See",
"      <a class=\"local\" href=\"#H22939433\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BWS usually occurs sporadically, but familial transmission occurs in approximately 15 percent of cases. (See",
"      <a class=\"local\" href=\"#H1618222\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deregulation of imprinted genes within the chromosome 11p15.5 region results in the BWS phenotype. However, a chromosome 11p15 molecular alteration is identified in only about 80 percent of individuals with BWS. This may be due to low level somatic mosaicism in the tissue sampled for testing or to other genomic loci that are probably involved in the etiology of BWS. (See",
"      <a class=\"local\" href=\"#H1618409\">",
"       'Genetics and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmark features of BWS are omphalocele (exomphalos), macroglossia, and macrosomia (gigantism). However, the clinical presentation is highly variable, and some cases lack these characteristic features. (See",
"      <a class=\"local\" href=\"#H130269\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of genetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epigenetic alterations in growth regulatory genes on chromosome 11p15.5 are associated with specific phenotype-(epi)genotype correlations and different recurrence risks. (See",
"      <a class=\"local\" href=\"#H1887409\">",
"       'Phenotype-(epi)genotype correlations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No consensus diagnostic criteria exist for BWS, although the presence of a subset of associated findings are used to confer a clinical diagnosis. Molecular testing can then be incorporated to determine the precise genetic defect and confirm the diagnosis. Methylation sensitive multiplex ligation probe analysis (MS-MLPA)",
"      <strong>",
"      </strong>",
"      is the most robust method available for detecting the majority of epigenetic and genetic etiologies associated with BWS. Prenatal testing is available. (See",
"      <a class=\"local\" href=\"#H1619903\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes both genetic and nongenetic causes of macrosomia (",
"      <a class=\"graphic graphic_table graphicRef53324 \" href=\"UTD.htm?1/51/1851\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62919 \" href=\"UTD.htm?32/44/33483\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22939447\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial evaluation includes assessment for hypoglycemia, airway sufficiency, feeding difficulties, and screening for tumors. Surveillance includes monitoring for hypoglycemia, tumors, developmental issues, and renal disease. (See",
"      <a class=\"local\" href=\"#H22939583\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cases involving UPD arise from post-zygotic somatic recombination and are therefore not known to be associated with a significantly increased risk for recurrence. Parental studies are recommended if genomic alterations are found (eg, karyotype abnormalities, CDKN1C mutations, or microduplications or microdeletions of the chromosome 11p15.5 region) and these test results are then incorporated into estimation of recurrence risks. (See",
"      <a class=\"local\" href=\"#H22939618\">",
"       'Genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with BWS are at increased risk for mortality mainly due to complications of prematurity, macroglossia, hypoglycemia, tumors, and, rarely, cardiomyopathy. The increased risk for neoplasia is concentrated in the first eight years of life. Thus, prognosis is generally favorable after early childhood. (See",
"      <a class=\"local\" href=\"#H1351427\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/1\">",
"      Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. Eur J Hum Genet 2010; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     Beckwith JB. Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of kidneys and pancreas, and Leydig-cell hyperplasia: Another syndrome? (Abstract), Western Society for Pediatric Research (Ed), Los Angeles 1963.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/3\">",
"      WIEDEMANN HR. [FAMILIAL MALFORMATION COMPLEX WITH UMBILICAL HERNIA AND MACROGLOSSIA--A \"NEW SYNDROME\"?]. J Genet Hum 1964; 13:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/4\">",
"      Pettenati MJ, Haines JL, Higgins RR, et al. Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet 1986; 74:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/5\">",
"      Weksberg R, Shuman C, Caluseriu O, et al. Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome. Hum Mol Genet 2002; 11:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/6\">",
"      Cooper WN, Luharia A, Evans GA, et al. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2005; 13:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/7\">",
"      Enklaar T, Zabel BU, Prawitt D. Beckwith-Wiedemann syndrome: multiple molecular mechanisms. Expert Rev Mol Med 2006; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/8\">",
"      Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2005; 137C:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/9\">",
"      Bliek J, Maas S, Alders M, et al. Epigenotype, phenotype, and tumors in patients with isolated hemihyperplasia. J Pediatr 2008; 153:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/10\">",
"      Meyer E, Lim D, Pasha S, et al. Germline mutation in NLRP2 (NALP2) in a familial imprinting disorder (Beckwith-Wiedemann Syndrome). PLoS Genet 2009; 5:e1000423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/11\">",
"      Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008; 40:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/12\">",
"      Naik S, Riordan-Eva E, Thomas NS, et al. Large de novo deletion of 7p15.1 to 7p12.1 involving the imprinted gene GRB10 associated with a complex phenotype including features of Beckwith Wiedemann syndrome. Eur J Med Genet 2011; 54:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/13\">",
"      Lirussi F, Jonard L, Gaston V, et al. Beckwith-Wiedemann-like macroglossia and 18q23 haploinsufficiency. Am J Med Genet A 2007; 143A:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/14\">",
"      Hark AT, Schoenherr CJ, Katz DJ, et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/15\">",
"      Smilinich NJ, Day CD, Fitzpatrick GV, et al. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A 1999; 96:8064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/16\">",
"      Diaz-Meyer N, Day CD, Khatod K, et al. Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet 2003; 40:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/17\">",
"      Weksberg R, Smith AC, Squire J, Sadowski P. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003; 12 Spec No 1:R61.",
"     </a>",
"    </li>",
"    <li>",
"     Weksberg R, Shuman C. Beckwith-Wiedemann syndrome and hemihypertrophy. In: Management of genetic syndromes, 2nd ed, Cassidy SB, Allanson JE (Eds), John Wiley &amp; Sons, Inc, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/19\">",
"      Niemitz EL, DeBaun MR, Fallon J, et al. Microdeletion of LIT1 in familial Beckwith-Wiedemann syndrome. Am J Hum Genet 2004; 75:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/20\">",
"      Prawitt D, Enklaar T, G&auml;rtner-Rupprecht B, et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci U S A 2005; 102:4085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/21\">",
"      Sparago A, Cerrato F, Vernucci M, et al. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004; 36:958.",
"     </a>",
"    </li>",
"    <li>",
"     Shuman C, Smith AC, Weksberg R. Beckwith-Wiedemann Syndrome. GeneReviews [Internet] 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/23\">",
"      Elliott M, Bayly R, Cole T, et al. Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet 1994; 46:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/24\">",
"      Weng EY, Moeschler JB, Graham JM Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. Am J Med Genet 1995; 56:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/25\">",
"      Wilson M, Peters G, Bennetts B, et al. The clinical phenotype of mosaicism for genome-wide paternal uniparental disomy: two new reports. Am J Med Genet A 2008; 146A:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/26\">",
"      Chitayat D, Rothchild A, Ling E, et al. Apparent postnatal onset of some manifestations of the Wiedemann-Beckwith syndrome. Am J Med Genet 1990; 36:434.",
"     </a>",
"    </li>",
"    <li>",
"     Weksberg R, The Hospital for Sick Children, Toronto, personal communication, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/28\">",
"      Hoyme HE, Seaver LH, Jones KL, et al. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 1998; 79:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/29\">",
"      Engstr&ouml;m W, Lindham S, Schofield P. Wiedemann-Beckwith syndrome. Eur J Pediatr 1988; 147:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/30\">",
"      Mart&iacute;nez y Mart&iacute;nez R, Ocampo-Campos R, P&eacute;rez-Arroyo R, et al. The Wiedemann-Beckwith syndrome in four sibs including one with associated congenital hypothyroidism. Eur J Pediatr 1985; 143:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/31\">",
"      Goldman M, Shuman C, Weksberg R, Rosenblum ND. Hypercalciuria in Beckwith-Wiedemann syndrome. J Pediatr 2003; 142:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/32\">",
"      Borer JG, Kaefer M, Barnewolt CE, et al. Renal findings on radiological followup of patients with Beckwith-Wiedemann syndrome. J Urol 1999; 161:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/33\">",
"      Choyke PL, Siegel MJ, Oz O, et al. Nonmalignant renal disease in pediatric patients with Beckwith-Wiedemann syndrome. AJR Am J Roentgenol 1998; 171:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/34\">",
"      Gardiner K, Chitayat D, Choufani S, et al. Brain abnormalities in patients with Beckwith-Wiedemann syndrome. Am J Med Genet A 2012; 158A:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/35\">",
"      Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol 2005; 8:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/36\">",
"      DeBaun MR, Siegel MJ, Choyke PL. Nephromegaly in infancy and early childhood: a risk factor for Wilms tumor in Beckwith-Wiedemann syndrome. J Pediatr 1998; 132:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/37\">",
"      Schneid H, Vazquez MP, Vacher C, et al. The Beckwith-Wiedemann syndrome phenotype and the risk of cancer. Med Pediatr Oncol 1997; 28:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/38\">",
"      Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. J Pediatr 1980; 96:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/39\">",
"      Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health 2006; 42:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/40\">",
"      Wiedemann HR. Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome (Letter to the Editor). Eur J Pediatr 1983; 141:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/41\">",
"      Kent L, Bowdin S, Kirby GA, et al. Beckwith Weidemann syndrome: a behavioral phenotype-genotype study. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/42\">",
"      Slavotinek A, Gaunt L, Donnai D. Paternally inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome. J Med Genet 1997; 34:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/43\">",
"      Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr 2004; 145:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/44\">",
"      Bliek J, Maas SM, Ruijter JM, et al. Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS. Hum Mol Genet 2001; 10:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/45\">",
"      DeBaun MR, Niemitz EL, McNeil DE, et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 2002; 70:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/46\">",
"      Rump P, Zeegers MP, van Essen AJ. Tumor risk in Beckwith-Wiedemann syndrome: A review and meta-analysis. Am J Med Genet A 2005; 136:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/47\">",
"      Scott RH, Douglas J, Baskcomb L, et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 2008; 40:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/48\">",
"      Weksberg R, Nishikawa J, Caluseriu O, et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet 2001; 10:2989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/49\">",
"      DeBaun MR, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 2003; 72:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/50\">",
"      Engel JR, Smallwood A, Harper A, et al. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet 2000; 37:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/51\">",
"      Waziri M, Patil SR, Hanson JW, Bartley JA. Abnormality of chromosome 11 in patients with features of Beckwith-Wiedemann syndrome. J Pediatr 1983; 102:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/52\">",
"      Smith AC, Rubin T, Shuman C, et al. New chromosome 11p15 epigenotypes identified in male monozygotic twins with Beckwith-Wiedemann syndrome. Cytogenet Genome Res 2006; 113:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/53\">",
"      Smith AC, Shuman C, Chitayat D, et al. Severe presentation of Beckwith-Wiedemann syndrome associated with high levels of constitutional paternal uniparental disomy for chromosome 11p15. Am J Med Genet A 2007; 143A:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/54\">",
"      Scott RH, Douglas J, Baskcomb L, et al. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet 2008; 45:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/55\">",
"      Bliek J, Verde G, Callaway J, et al. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. Eur J Hum Genet 2009; 17:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/56\">",
"      Hatada I, Nabetani A, Morisaki H, et al. New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Hum Genet 1997; 100:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/57\">",
"      Lee MP, DeBaun M, Randhawa G, et al. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997; 61:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/58\">",
"      Gicquel C, Gaston V, Mandelbaum J, et al. In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene. Am J Hum Genet 2003; 72:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/59\">",
"      Halliday J, Oke K, Breheny S, et al. Beckwith-Wiedemann syndrome and IVF: a case-control study. Am J Hum Genet 2004; 75:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/60\">",
"      Maher ER, Afnan M, Barratt CL. Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs? Hum Reprod 2003; 18:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/61\">",
"      Li M, Squire J, Shuman C, et al. Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations. Genomics 2001; 74:370.",
"     </a>",
"    </li>",
"    <li>",
"     Baskin B, Molecular Genetics Specialist, Pediatric Laboratory Medicine, The Hospital for Sick Children, personal communication, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/63\">",
"      Storm DW, Hirselj DA, Rink B, et al. The prenatal diagnosis of Beckwith-Wiedemann syndrome using ultrasound and magnetic resonance imaging. Urology 2011; 77:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/64\">",
"      Wilkins-Haug L, Porter A, Hawley P, Benson CB. Isolated fetal omphalocele, Beckwith-Wiedemann syndrome, and assisted reproductive technologies. Birth Defects Res A Clin Mol Teratol 2009; 85:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/65\">",
"      Souka AP, Snijders RJ, Novakov A, et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998; 11:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/66\">",
"      Ballock RT, Wiesner GL, Myers MT, Thompson GH. Hemihypertrophy. Concepts and controversies. J Bone Joint Surg Am 1997; 79:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/67\">",
"      Leung AK, Fong JH, Leong AG. Hemihypertrophy. J R Soc Promot Health 2002; 122:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/68\">",
"      Jones SM, Rahman RS, Bourgeois DJ 3rd, et al. Hemihyperplasia in a 4-month-old. Clin Pediatr (Phila) 2011; 50:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/69\">",
"      Eggermann T, Sch&ouml;nherr N, Meyer E, et al. Epigenetic mutations in 11p15 in Silver-Russell syndrome are restricted to the telomeric imprinting domain. J Med Genet 2006; 43:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/70\">",
"      Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 1998; 79:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/71\">",
"      Kimura Y, Kamada Y, Kimura S. Anesthetic management of two cases of Beckwith-Wiedemann syndrome. J Anesth 2008; 22:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/72\">",
"      Tomlinson JK, Morse SA, Bernard SP, et al. Long-term outcomes of surgical tongue reduction in Beckwith-Wiedemann syndrome. Plast Reconstr Surg 2007; 119:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/73\">",
"      Teplick A, Kowalski M, Biegel JA, Nichols KE. Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician. Eur J Pediatr 2011; 170:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/74\">",
"      Clericuzio CL, Martin RA. Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia. Genet Med 2009; 11:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/75\">",
"      Zarate YA, Mena R, Martin LJ, et al. Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol. Am J Med Genet A 2009; 149A:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/76\">",
"      Everman DB, Shuman C, Dzolganovski B, et al. Serum alpha-fetoprotein levels in Beckwith-Wiedemann syndrome. J Pediatr 2000; 137:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/77\">",
"      Clericuzio CL, Chen E, McNeil DE, et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J Pediatr 2003; 143:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24473/abstract/78\">",
"      Greer KJ, Kirkpatrick SJ, Weksberg R, Pauli RM. Beckwith-Wiedemann syndrome in adults: observations from one family and recommendations for care. Am J Med Genet A 2008; 146A:1707.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13555 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-7D7969DF47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24473=[""].join("\n");
var outline_f23_57_24473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1620147\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22939433\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1618222\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1618409\">",
"      GENETICS AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130269\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351639\">",
"      Prenatal and perinatal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351646\">",
"      Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351653\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351660\">",
"      Structural anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351667\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351674\">",
"      Development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1887409\">",
"      PHENOTYPE-(EPI)GENOTYPE CORRELATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887416\">",
"      Tumor development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887423\">",
"      Hemihyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887430\">",
"      Omphalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887437\">",
"      Developmental delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887444\">",
"      Severe BWS phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887451\">",
"      Positive family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887458\">",
"      Female monozygotic twins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887465\">",
"      Infertility/assisted reproductive technology (ART)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1619903\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1619017\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887889\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22939447\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22939583\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22939591\">",
"      Evaluation following initial diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22939600\">",
"      Treatment of manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22939609\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22939618\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1351427\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1620147\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13555|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/36/29248\" title=\"figure 1\">",
"      Imprinting--pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/51/27455\" title=\"figure 2\">",
"      Diastasis recti",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13555|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/35/43571\" title=\"picture 1\">",
"      Hemihyperplasia in a patient with Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/19/10545\" title=\"picture 2\">",
"      Macroglossia in a patient with Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/60/17359\" title=\"picture 3\">",
"      Umbilical hernia in a patient with Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/16/4354\" title=\"picture 4\">",
"      Anterior ear lobe crease and posterior helical ear pits - BWS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13555|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/51/1851\" title=\"table 1\">",
"      Risk factors macrosomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/44/33483\" title=\"table 2\">",
"      Differential diagnosis of BWS - Genetic disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=related_link\">",
"      Basic principles of genetic counseling for the obstetrical provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_57_24474="Neonatal lupus";
var content_f23_57_24474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal lupus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Jill P Buyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24474/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/57/24474/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/57/24474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal lupus (NL) is a passively transferred autoimmune disease. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus (SLE) and Sj&ouml;gren&rsquo;s syndrome, and antibodies to",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, many cases occur in children of mothers who have the same autoantibodies, but who do not have symptoms of lupus or other autoimmune disease at the time of the baby's birth. About half of these mothers go on to develop autoimmune disease (more commonly Sj&ouml;gren syndrome than SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/3\">",
"     3",
"    </a>",
"    ]. The most serious complication of NL is complete heart block (about 10 percent have an associated cardiomyopathy at the initial diagnosis or develop it later).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal lupus (NL) is presumed to result from transplacental passage of maternal",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies. Ro and La molecules are thought to form a single particle that is present in all cells. The precise mechanism of injury to specific tissues, such as the skin and heart, is not known. The pathogenesis of disease probably involves more than simple transplacental passage of antibodies, since the disease is rare, even in mothers who have these antibodies, and there can be discordance of disease even in monozygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies are associated with a variety of clinical syndromes in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have established the association between",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies and NL by prospectively monitoring offspring of women with",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 100 women with",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies and an autoimmune disease who were prospectively monitored, beginning prior to conception, only two of the mothers had pregnancies that were complicated by congenital complete heart block (detected by fetal echocardiography at 20 and 22 weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/6\">",
"       6",
"      </a>",
"      ]. The incidence of complete heart block was 2 percent (95% CI 0.5-7 percent) in first-observed pregnancies, 1.8 percent of live births, and 1.7 percent of all pregnancies.",
"     </li>",
"     <li>",
"      A similar risk was noted in two other reports. In one series of 124 pregnancies in 112 women with",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies, with or without",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies, the risk was 1.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/7\">",
"       7",
"      </a>",
"      ]. In another series of women with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro,",
"      </span>",
"      1 of 99 first-observed pregnancies was complicated by complete heart block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective study of 98",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      exposed pregnancies, three offspring had first degree block, three had third degree block, and four had cutaneous neonatal lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are consistent with a crude estimate based upon the 0.5 percent prevalence of",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies in asymptomatic pregnant women and the rate of congenital heart block (1 in 15,000 to 1 in 22,000 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most infants with complete heart block have a mother with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies. This was illustrated in one report, in which",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies were present in 100 and 91 percent of 57 mothers of infants with complete heart block, and 91 and 73 percent of 12 mothers of infants with transient cutaneous NL. Similar values in mothers of infants with complete heart block (100 and 68 percent) were noted by the Research Registry for Neonatal Lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast,",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies were present in only 47 and 15 percent of 152 mothers with lupus and related autoimmune diseases who gave birth to healthy infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported a lower risk of NL in offspring of women with anti-idiotype antibodies to",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of cardiac manifestations of neonatal lupus (cardiac-NL) increases in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of cardiac-NL rises to about 17 percent",
"      <span class=\"nowrap\">",
"       (28/161)",
"      </span>",
"      in women with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies who have had a previous child with congenital heart block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/13\">",
"       13",
"      </a>",
"      ]. These infants included 22 with complete (third degree heart block), three with endocardial fibroelastosis, two with second degree heart block, and one with first degree heart block. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Maternal features'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The risk of cardiac-NL is similarly elevated in offspring of women with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies who had a previous child with cutaneous neonatal lupus without cardiac manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/14\">",
"       14",
"      </a>",
"      ]. The overall recurrence rate of neonatal lupus in 77 pregnancies of 58 women in this series was 49 percent, and 18 percent of these pregnancies were complicated by cardiac-NL. A subset analysis restricted to the 39 children born after the initial child with cutaneous NL was enrolled found an overall recurrence rate for NL of 36 percent (95% CI: 20-52 percent). Five pregnancies (12.8 percent) were complicated by cardiac-NL and nine (23.1 percent) by cutaneous NL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of congenital complete heart block also appears to be more common in offspring of women with high titers of",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    compared with mothers with low titers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/11,15-17\">",
"     11,15-17",
"    </a>",
"    ], although there is considerable overlap in antibody titers between affected and unaffected cases and most women have high titers that remain stable over time. The risk of heart block was slightly higher in one study if a mother had antibodies to both",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/16\">",
"     16",
"    </a>",
"    ], but was independent of",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    titers in another [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     52 kD component of SSA/Ro",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the traditional Ro antigen of 60kD, another antigen of 52kD has been identified. Whether this second antigen is really &ldquo;Ro&rdquo; remains controversial since the Ro52 does not contain an RNA binding domain. Antibodies with a specificity for the 52 kD component of the",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    protein (Ro52) are more frequently found and are present at higher concentrations in the serum of children with congenital heart block (CHB) and their mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ]. In the Research Registry for Neonatal Lupus, 83 percent of mothers with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies and infants with CHB had anti-52 kD antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is conflicting data on whether the primary specificity of these antibodies is an important determinant of risk. As an example, maternal anti-52 kD antibodies with primary specificity for a particular peptide fragment (amino acids 200 through 239, p200-239) are significantly associated with the development of CHB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In contrast, women with anti-52 kD antibodies who gave birth to healthy children had antibodies that predominantly bound a different epitope (amino acids 177-196, p177-196). However, maternal anti-p200 antibody exposure was observed in equal frequency in both affected and unaffected offspring in a study from the Research Registry for Neonatal Lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/21\">",
"     21",
"    </a>",
"    ]. In another study, higher levels of Ro52 p200 antibodies were seen in mothers of children with CHB than those with normal children, although these antibodies still occurred in women with unaffected children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/22\">",
"     22",
"    </a>",
"    ]. These results suggest that additional factors are necessary to convert risk (ie, antibody exposure) to disease expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Role in cutaneous lupus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one prospective study of women with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies, cutaneous NL was present in 21 of 128 neonates (16 percent) and was significantly more frequent in those with both",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/7\">",
"     7",
"    </a>",
"    ]. In another study, infants exposed to high titers of",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    were more likely to have noncardiac manifestations of neonatal lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\", section on 'Skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Role in heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis is not fully elucidated, it is suspected that heart block results from binding of",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies to fetal cardiac tissue, leading to autoimmune injury of the atrioventricular (AV) node and its surrounding tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4,23,24\">",
"     4,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an in vitro study, apoptosis induced translocation of",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    to the surface of fetal cardiomyocytes;",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies were then able to bind to the surface of the fetal cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/25\">",
"     25",
"    </a>",
"    ]. In another study, healthy fetal cardiomyocytes in cell culture were capable of phagocytosing neighboring apoptotic cardiomyocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/26\">",
"     26",
"    </a>",
"    ]. It is hypothesized that this function may be a mechanism whereby healthy cardiomyocytes contribute to inflammation-free physiologic remodeling of the human fetal heart.",
"   </p>",
"   <p>",
"    Further research revealed that \"physiologic\" uptake by cardiomyocytes was prevented when",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    antibodies bound to apoptotic cardiomyocytes, diverting these opsonized cardiomyocytes to uptake by macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/26\">",
"     26",
"    </a>",
"    ]. These antibody-coated cardiomyocytes induce macrophages to release proinflammatory cytokines, resulting in inflammation-induced tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/27\">",
"     27",
"    </a>",
"    ]. Tumor necrosis factor alpha may potentiate the inflammatory component and transforming growth factor beta may be important in causing fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to inducing tissue damage,",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies may inhibit calcium channel activation or the cardiac L- and T-type calcium channels themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. L-type channels are crucial to action potential propagation and conduction in the AV and SA nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other evidence suggests that the presence of maternal antibodies to",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     SSB/La,",
"    </span>",
"    although a powerful risk factor for congenital heart block (CHB), is not the only determinant of the development of NL, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal antibodies to other antigens may cause neonatal disease in some cases. As an example, anti-U1 RNP antibodies in the absence of",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies were found in a few instances [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. These patients had the classic rash of NL, but not congenital heart block. There is one report of cardiac injury associated with anti-RNP absent",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro-SSB/La,",
"      </span>",
"      and that was transient first degree block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The fact that heart block develops in only a minority of subsequent pregnancies, despite the persistence of maternal",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies, strongly suggests that fetal factors are important determinants of risk. There is evidence in Japanese and European population that fetal susceptibility may be influenced by specific HLA alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. However, the discordance of heart block in identical twins suggests that in utero factors in addition to genetic differences play a role [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic factors in the infant, in particular the HLA alleles DQB1*02, DRB1*03, and a polymorphism in the promoter region of the gene for tumor necrosis factor alpha (-308A, associated with higher TNFa production) may play a role in skin disease. In a group of 22 children who had a characteristic NL rash, the frequency of carriage of all three alleles was twice that of siblings who had either CHB or were unaffected [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/38\">",
"       38",
"      </a>",
"      ]. The most significant associations were found in the HLA region in the first genome wide association study of cardiac manifestations of NL that included 116 children of European ancestry [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maternal-fetal microchimerism may contribute to CHB in NL. This was illustrated in an autopsy study of one fetal and three postnatal deaths related to heart block associated with maternal lupus or the presence of",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/39\">",
"       39",
"      </a>",
"      ]. Female, presumably maternal, cells were found in the myocardium in all four of the males with heart block and in two of four controls. Increased numbers of female cells were found in the myocardium of the male fetus and infants with heart block. Some of the maternal cells in the myocardium expressed differentiation markers of myocytes. Others had surface markers of hematopoietic cells. The pathogenetic implications of these findings are uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <span class=\"nowrap\">",
"     fetus/newborn",
"    </span>",
"    can have either cardiac or cutaneous findings or both as the major manifestations of neonatal lupus (NL). Cardiac manifestations usually occur between 18 to 24 weeks of gestation. The rash can be present at birth, but is more often observed after birth. It can appear up to about four months of age. Other hepatobiliary and hematologic manifestations also may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rash of NL usually is comprised of erythematous annular lesions or arcuate macules with slight central atrophy and raised active margins that are located primarily on the scalp and periorbital area, although the rash is sometimes seen on other parts of the body. The rash is often confused with a fungal skin infection or seborrheic dermatitis (see",
"    <a class=\"local\" href=\"#H4219076\">",
"     'Differential diagnosis'",
"    </a>",
"    below). The rash is noted at delivery in some cases, but may not develop until after exposure to UV light [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/40\">",
"     40",
"    </a>",
"    ]. In a cohort of 57 infants, the rash was recognized at a mean of 6 weeks and lasted an average of 17 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/41\">",
"     41",
"    </a>",
"    ]. The rash is usually self-limiting and almost always resolves by six to eight months of age because the half-life of IgG antibodies is approximately 21 to 25 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathology of the erythematous-desquamative lesions more closely resembles that of subacute cutaneous lupus erythematosus than discoid lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/40\">",
"     40",
"    </a>",
"    ]. Typical findings are vacuolar alterations at the dermoepidermal interface and adnexal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/43\">",
"     43",
"    </a>",
"    ]. Some patients present with urticaria-like lesions that have superficial and deep perivascular and periadnexal lymphocytic infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital complete heart block is the most serious manifestation of NL. NL is responsible for 80 to 95 percent of all cases of congenital complete heart block diagnosed in utero or in the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/5,44,45\">",
"     5,44,45",
"    </a>",
"    ]. NL is a much less common cause of heart block presenting after the neonatal period (5 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/44\">",
"     44",
"    </a>",
"    ]. The clinical manifestations of complete heart block are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second degree block detected in utero and first or second degree heart block found in infants at birth, can progress to complete heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. It remains unclear whether first degree block (defined in some series as a PR interval &gt;150 msec) detected in utero progresses to more advanced block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/9\">",
"     9",
"    </a>",
"    ]. The absence of substantial evidence is due in part to the fact that treatment is often provided to mothers with fetuses with first degree block and there is variability in both the technique of detection and cutoff values to define first degree heart block among the different studies. In one series of",
"    <span class=\"nowrap\">",
"     anti-Ro/La",
"    </span>",
"    antibody-positive pregnant women that were referred for serial fetal echocardiography, fetuses with either atrioventricular (AV) prolongation or Mobitz type 1 second degree block were not treated and none developed progressive heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/49\">",
"     49",
"    </a>",
"    ]. Three of these 15 fetuses had a neonatal diagnosis of first degree block that spontaneously resolved in two and did not progress in one on follow-up examinations.",
"   </p>",
"   <p>",
"    The sinoatrial (SA) node also may be involved in NL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/4,23,46,50\">",
"     4,23,46,50",
"    </a>",
"    ]. Involvement occurs with a frequency of 3 to 4 percent in fetuses with conduction abnormalities exposed to maternal",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies. The dysrhythmia is usually not permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/46\">",
"     46",
"    </a>",
"    ] and if sustained carries a good prognosis if not associated with endocardial fibroelastosis (EFE), ventricular dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AV nodal block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In at-risk pregnancies, sinus bradycardia has been described in 3.8 percent of fetuses that were monitored ultrasonographically, but this dysrhythmia is usually not permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other arrhythmias and conduction abnormalities have been reported, but are generally not clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Autoantibody-mediated heart block in NL is typically associated with a structurally normal heart; however, structural abnormalities such as valvular lesions are occasionally reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/53\">",
"     53",
"    </a>",
"    ]. Additional cardiac abnormalities that may be associated with NL include congestive heart failure due to cardiomyopathy that is often associated with endocardial fibroelastosis or on rare occasions with myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/54\">",
"     54",
"    </a>",
"    ]. The following observations illustrate the range of other cardiac manifestations reported in patients with NL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial observations suggesting that right bundle branch block and prolonged QT interval were associated with",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/55\">",
"       55",
"      </a>",
"      ] were not confirmed by other investigators [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Structural heart disease has been reported occasionally in association with NL. However, caution is needed in interpreting such reports because some structural abnormalities may cause heart block per se (eg, L-transposition of the great vessels with a single ventricle, heterotaxia, and atrioventricular septal defects). Of these anomalies, only VSD has been reported in association with NL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/47,56,57\">",
"       47,56,57",
"      </a>",
"      ]. In one of these cases, the small VSD was not thought to be responsible for CHB [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other congenital structural cardiac anomalies have been observed in association with NL (persistent patent ductus arteriosus, patent foramen ovale, pulmonic stenosis, pulmonary valvular dysplasia, fusion of chordae tendineae of the tricuspid valve, and ostium secundum type atrial septal defects [ASD]) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/47,58\">",
"       47,58",
"      </a>",
"      ]. In one report of children born to women with SLE, ostium secundum ASDs were present in 2 of 90 neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/58\">",
"       58",
"      </a>",
"      ], and, in another series, ASDs were found in 6 of 133 with NL and CHB [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NL with CHB has been associated with endocardial fibroelastosis (EFE) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/44,59\">",
"       44,59",
"      </a>",
"      ]. In a report of 13 affected children, seven had EFE at presentation (four fetal and three postnatal), and six developed EFE weeks to as long as five years after the diagnosis of complete heart block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/59\">",
"       59",
"      </a>",
"      ]. Eleven either died or underwent cardiac transplantation because of the EFE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H1978642#H1978642\">",
"       \"Definition and classification of the cardiomyopathies\", section on 'Endocardial fibroelastosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      EFE has also been reported in the absence of a conduction defect in infants with maternal anti-Ro and anti-La antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was no histopathologic confirmation, only suggestive echocardiographic findings of cardiomegaly and of moderate mitral and tricuspid valvular regurgitation, in one case report in which myocarditis was suspected to be associated with NL and CHB [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/62\">",
"       62",
"      </a>",
"      ]. Pacing alone was insufficient treatment, but improvement in heart failure was seen after initiation of glucocorticoid therapy. Death resulting from myocarditis occurred at 20 months of age in another child with NL and CHB [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to rash and cardiac abnormalities, there may be other manifestations of NL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic manifestations include asymptomatic elevated liver function tests, mild hepatosplenomegaly, cholestasis, and hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/40,63,64\">",
"       40,63,64",
"      </a>",
"      ]. In one report, hepatobiliary disease occurred in 19 of 219 infants (9 percent) with neonatal lupus, usually in conjunction with either cardiac or cutaneous involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/65\">",
"       65",
"      </a>",
"      ]. In another series of 54 infants, 15 percent had transiently elevated transaminase levels [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematologic manifestations also have been described, including anemia, neutropenia, thrombocytopenia and, rarely, aplastic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/40,63,64,66,67\">",
"       40,63,64,66,67",
"      </a>",
"      ]. Neutropenia was present in 25 of 107 infants born to mothers with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies in one prospective study, but no cases of neonatal sepsis occurred in neutropenic children [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic manifestations have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/40\">",
"       40",
"      </a>",
"      ], but whether there is an association with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      antibodies is uncertain. In one study from Toronto, 7 of 87 infants exposed to maternal",
"      <span class=\"nowrap\">",
"       SSA/Ro",
"      </span>",
"      were reported to have hydrocephalus and 10 with macrocephaly [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/68\">",
"       68",
"      </a>",
"      ]. These findings have not been published in other cohorts of",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      exposed children. In a study from New York, there was a trend toward higher parental reporting of neuropsychiatric dysfunction in children with NL compared with normal friend controls [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A unique radiographic finding of NL is stippling of the epiphyses (chondrodysplasia punctata) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific diagnostic criteria for neonatal lupus (NL). The diagnosis of NL is made when a fetus or newborn of a mother with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La,",
"    </span>",
"    or possibly anti-RNP, antibodies develops heart block",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the typical rash or hepatic or hematologic manifestations in the absence of another explanation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations for prenatal screening and postnatal diagnosis are based upon the potential cardiac manifestations of neonatal lupus (NL) and their associated morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal screening for",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies is warranted for women who are known to be at risk of having a pregnancy complicated by NL. Women who are more likely to have",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies include those with lupus, Sj&ouml;gren syndrome, an undifferentiated autoimmune disease, or NL in a previous pregnancy. Women with these identifiable risk factors should be tested before conception or as early in pregnancy as possible.",
"   </p>",
"   <p>",
"    NL in an offspring can be the first sign that the mother has",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies. These antibodies are not part of routine prenatal testing in asymptomatic women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4219179\">",
"    <span class=\"h2\">",
"     In utero monitoring for heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who test positive for",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    autoantibodies may benefit from more intensive assessment for fetal heart block with frequent fetal echocardiographic testing during pregnancy. There are no formal guidelines for the type or the frequency of testing to detect fetal heart block, but performing weekly pulsed Doppler fetal echocardiography from the 18th through the 26th week of pregnancy and then every other week until 32 weeks should be strongly considered. The most vulnerable period for the fetus is during the period from 18 to 24 weeks gestation. Normal sinus rhythm can progress to complete block in seven days during this high-risk period. New onset of heart block is less likely during the 26th through the 30th week, and it rarely develops after 30 weeks of pregnancy.",
"   </p>",
"   <p>",
"    Women with low titer antibodies are less likely to have offspring with cardiac-NL than women with high titers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/17\">",
"     17",
"    </a>",
"    ]. The problem is that laboratories have different cutoff values and most women with these antibodies have high titers.",
"   </p>",
"   <p>",
"    Complete heart block (and usually second degree block) results in fetal bradycardia that can be detected by routine fetal auscultation, ultrasonography (sonogram), or echocardiography. Less-advanced degrees of heart block can be detected in utero by pulsed Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/70\">",
"     70",
"    </a>",
"    ]. This technique depends upon measurement of the mechanical PR interval as determined from the onset of atrial contraction (initiation of mitral valve movement) to ventricular contraction (aortic pulsation). Additional diagnostic modalities include fetal magnetocardiography (MCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/71\">",
"     71",
"    </a>",
"    ] and electrocardiography (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/72\">",
"     72",
"    </a>",
"    ]. The use of echocardiographic monitoring may present a way to more selectively use interventions to prevent or reverse the development of more advanced heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/9,73-75\">",
"     9,73-75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following prospective studies illustrate these points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the United States, 95 women with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      antibodies were evaluated during 98 pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/9\">",
"       9",
"      </a>",
"      ]. Fetal echocardiograms were performed weekly from 16 to 26 weeks gestation and biweekly from 26 to 34 weeks. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ninety-two fetuses had normal PR intervals.",
"     </li>",
"     <li>",
"      NL developed in 10 infants, including four patients with only NL rash.",
"     </li>",
"     <li>",
"      Three fetuses had third degree heart block, detected between 20 and 23 weeks. None of them had a preceding PR interval &gt;150 msec, although in two cases, more than one week had elapsed between echocardiographic evaluations. Third degree block persisted despite maternal treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . Two of these cases were terminated because of severe hydrops.",
"     </li>",
"     <li>",
"      Two fetuses had first degree heart block (defined as a PR interval &gt;150 msec, 3 SD above the mean) detected at or before 22 weeks gestation that resolved within one week with maternal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      therapy (4 mg dose). The ECG of one additional newborn revealed a prolonged PR interval persistent at three years despite normal intervals throughout gestation.",
"     </li>",
"     <li>",
"      Prolonged PR intervals &le;150 msec were not considered first degree block and often spontaneously regressed to shorter intervals.",
"     </li>",
"     <li>",
"      No first degree block developed after a normal ECG at birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Swedish case series, 24 pregnancies in women identified with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      52 kd antibodies were monitored by echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/75\">",
"       75",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One fetus developed second degree heart block at 23 weeks that improved to first degree atrioventricular (AV) block following initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      Another fetus progressed from first degree AV block (in this study defined as a PR interval of 140 msec) to complete heart block at 20 weeks. Complete heart block persisted despite treatment with fluorinated glucocorticoids.",
"     </li>",
"     <li>",
"      One-third of all the monitored fetuses had increased atrioventricular conduction times when compared to the 95 percent confidence limits for reference pregnancies (approximately 125 to 135 msec).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caution should be exercised when applying results from different studies, since the definition of an abnormal prolonged PR interval varied. In some cases, the decision to treat threshold was higher than a commonly used threshold of 2 SD above the mean PR interval of a control population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4219069\">",
"    <span class=\"h2\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for maternal",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies should be performed in any neonate with heart block absent causal structural abnormalities, because these antibodies account for 80 to 95 percent of reported cases of CHB in the fetus and neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/5,44,45\">",
"     5,44,45",
"    </a>",
"    ]. Infants up to eight months of age with an annular or polycyclic rash",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    any degree of heart block should be tested for",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies. A positive test in the child or mother fulfills the diagnostic criteria for NL.",
"   </p>",
"   <p>",
"    An infant diagnosed with NL who has compatible clinical manifestations and detectable autoantibodies (ie,",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    in the mother or infant), but no electrocardiographic evidence of heart block of any degree at birth, is at very low risk of subsequently developing conducting system disease. However, there have been rare cases of isolated cardiomyopathy reported in the Research Registry for Neonatal Lupus, one of which was fatal. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4219076\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes various rashes seen in the newborn period. These other rashes are not associated with maternal",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro,",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La,",
"    </span>",
"    or anti-RNP antibodies or with congenital heart block.",
"   </p>",
"   <p>",
"    The differential diagnosis of isolated polycyclic skin lesions in a newborn or neonate includes the following diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urticaria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Erythema marginatum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Erythema marginatum'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tinea corporis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seborrheic dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ichthyosiform genodermatosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H3#H3\">",
"       \"The genodermatoses\", section on 'Ichthyosiform dermatoses'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of isolated annular erythematous lesions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema annulare centrifugum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H25#H25\">",
"       \"Dermatophyte (tinea) infections\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial annular erythema",
"     </li>",
"     <li>",
"      Erythema multiforme (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link&amp;anchor=H25#H25\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\", section on 'Nosologic controversies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infantile epidermodysplastic erythema",
"     </li>",
"     <li>",
"      Pityrosporum (Malassezia species) dermal infection",
"     </li>",
"     <li>",
"      Annular erythema of infancy",
"     </li>",
"     <li>",
"      Erythema gyratum atrophicans",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lysinuric protein intolerance, a rare autosomal recessive disorder (MIM 222700) due to defective transport of cationic amino acids in the gut and kidney, may present with clinical features that are suggestive of SLE or NL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of congenital heart block is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4218950\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;This discussion emphasizes issues related to the treatment and potential prevention of neonatal lupus (NL). Testing for candidate antibodies is important prior to initiating therapy for a presumed case of cardiac neonatal lupus (cardiac-NL), because there are cases of heart block not associated with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     SSB/La.",
"    </span>",
"    In one study of 45 consecutive cases of congenital heart block, nine of the infants were antibody negative for",
"    <span class=\"nowrap\">",
"     SSA/Ro",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     SSB/La,",
"    </span>",
"    three of whom died [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/5\">",
"     5",
"    </a>",
"    ]. The specific indications for cardiac pacing in infants with congenital complete heart block are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treating fetal heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block is irreversible even with glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/5,75,80\">",
"     5,75,80",
"    </a>",
"    ]. Second degree heart block may be reversible, but it also may progress to complete heart block despite therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/46,80,81\">",
"     46,80,81",
"    </a>",
"    ]. The clinical relevance of first degree heart block is unclear, since progression from first degree block (defined as longer than 150 msec) to more advanced heart block in untreated fetuses has not been well documented. Fluorinated glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    , which are",
"    <strong>",
"     not",
"    </strong>",
"    inactivated by placental 11-beta hydroxysteroid dehydrogenase, may suppress the associated pleuropericardial effusion or hydrops and may improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential usefulness of in utero treatment with fluorinated glucocorticoids was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, four fetuses with second degree heart block treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      reverted to first degree block by birth [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/80\">",
"       80",
"      </a>",
"      ]. In comparison, two patients with second degree heart block in utero who were not treated with fluorinated glucocorticoids progressed to complete heart block.",
"     </li>",
"     <li>",
"      A multicenter, open-label, nonrandomized study involving 30 pregnancies evaluated the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/82\">",
"       82",
"      </a>",
"      ]. There was no reversal in the 31 fetuses with third degree block regardless of whether they were treated (n = 22) or not (n = 9). Of the six treated fetuses with second degree block, three remained in second degree block, two reverted to normal sinus rhythm (NSR), and one progressed to third degree block. Of the two treated fetuses with first degree block, both converted to NSR within one week. The one untreated patient with first degree block detected at 38 weeks gestation had NSR at birth.",
"     </li>",
"     <li>",
"      In a prospective study reviewed previously [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/9\">",
"       9",
"      </a>",
"      ], two fetuses had first degree heart block (defined as a PR interval &gt;150 msec, 3 SD above the mean) detected at or before 22 weeks gestation that resolved within one week with maternal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      therapy (4 mg dose). One infant had a prolonged PR interval detected at birth that persisted at three years despite normal intervals throughout gestation.",
"     </li>",
"     <li>",
"      Another multicenter, prospective study using tissue velocity-based fetal kinetocardiogram to detect atrioventricular (AV) block diagnosed first degree heart block (AV conduction time &gt;2 z scores above the normal mean) in six of 70 fetuses of 56 mothers positive for",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/83\">",
"       83",
"      </a>",
"      ]. Mothers were treated immediately with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and normalization of AV conduction was seen in all affected fetuses within two weeks. No fetuses were diagnosed with second or third degree heart block.",
"     </li>",
"     <li>",
"      In a retrospective series of 37 patients with complete heart block, the one-year survival rate in the 21 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      was 90 percent, compared with a survival rate of 46 percent in the 16 untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are risks of glucocorticoid therapy to both the mother (eg, infection, hypertension, avascular necrosis, insulin resistance, and gestational diabetes) and the infant (eg, oligohydramnios, growth restriction, and the still undetermined potential effect upon neurocognitive development) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following suggestions for in utero treatment are based upon observational data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal treatment with fluorinated glucocorticoids (eg, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      4 mg per day, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      3 mg per day) is suggested for mothers of fetuses with second degree heart block, beginning as soon after detection as is feasible and continuing through the end of pregnancy depending upon the response. Glucocorticoid therapy is usually discontinued after one week if heart block progresses to third degree block with no other signs of myocarditis. However, this is not uniformly agreed upon.",
"     </li>",
"     <li>",
"      Treatment of third degree block with glucocorticoids is somewhat controversial. It is generally",
"      <strong>",
"       not",
"      </strong>",
"      advised, unless there are other factors that indicate glucocorticoid treatment (eg, suspected myocarditis), since reversal of third degree block has not been documented. Some centers treat third degree block with glucocorticoids to prevent development of cardiomyopathy, although to date this has only been the experience at one center [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/84,86\">",
"       84,86",
"      </a>",
"      ]. Most patients with third degree block will require cardiac pacing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link&amp;anchor=H8#H8\">",
"       \"Congenital third degree (complete) atrioventricular block\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of isolated first degree block is controversial, because of the risks of therapy, the evidence that first degree block can revert to normal sinus rhythm without therapy, and the absence of consistent evidence that untreated first degree block can progress to more advanced block. Some centers prefer the watch-and-wait approach in most cases, while others treat all first degree block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/83,87\">",
"       83,87",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Heart block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluorinated glucocorticoids are also considered for signs of a more global cardiomyopathy. However, the effectiveness of these agents in the treatment of endocardial fibroelastosis is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/44\">",
"       44",
"      </a>",
"      ]. In an interinstitutional study from Toronto, a retrospective review of the use of glucocorticoids and IVIG (both in utero and after birth) suggested a potential survival benefit in cases associated with",
"      <span class=\"nowrap\">",
"       cardiomyopathy/endocardial",
"      </span>",
"      fibroelastosis based upon comparison to historical control data supporting an 85 percent demise [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/88\">",
"       88",
"      </a>",
"      ]. A study from France reported five cases of anti-Ro associated endocardial fibroelastosis absent conduction abnormalities, three of whom did well without IVIG [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Preemptive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive treatment of pregnant women who have",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies is another possible approach that is under exploration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"     \"Pregnancy in women with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventive treatment with glucocorticoids is",
"      <strong>",
"       not",
"      </strong>",
"      recommended, even in mothers with a previously affected fetus, despite its potential efficacy, because the risks of these medications in the majority of expectant mothers and their fetuses who would be unnecessarily exposed do not outweigh the potential benefits.",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIG) is also",
"      <strong>",
"       not",
"      </strong>",
"      recommended. In two multicenter, prospective observational studies, IVIG at replacement doses (400",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      given every three weeks from weeks 12 to 24, was not effective in preventing congenital heart block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]. It is unknown whether higher doses would be efficacious.",
"     </li>",
"     <li>",
"      We suggest preemptive treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (400 mg orally once a day) in pregnant women with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      antibodies who have previously given birth to a child with cardiac manifestations of neonatal lupus (cardiac-NL), regardless of maternal health status. Hydroxychloroquine should be initiated between 6 and 10 weeks gestation in women who are not already on the medication. Hydroxychloroquine is an antimalarial drug that inhibits ligation of endosomal Toll-like receptors. It is often used during pregnancies complicated by lupus and considered of minimal risk to the fetus and mother. An initial case-control study restricted to mothers with SLE (to avoid confounding by indication) suggested that hydroxychloroquine may decrease the overall risk of cardiac-NL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/91\">",
"       91",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A subsequent retrospective study based upon data from neonatal lupus registries in the United States, France, and the United Kingdom supports the efficacy of hydroxychloroquine in reducing the recurrence rate of cardiac-NL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/92\">",
"       92",
"      </a>",
"      ]. This study included pregnancies of women who had previously given birth to a child with cardiac-NL and had",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      antibodies, regardless of maternal health status (ie, the mother could have been asymptomatic at the time of pregnancy or have had an associated autoimmune disease). Two hundred fifty-seven pregnancies (40 exposed and 217 unexposed to hydroxychloroquine) were identified. Cardiac-NL developed in 3 of 40 (7.5 percent) of exposed fetuses and 46 of 217 (21.2 percent) of unexposed fetuses, with 10 fatalities in the unexposed group. A prospective open label study (not randomized because of the rarity of the disease) to confirm these observations is ongoing (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"       clinicaltrials.gov",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Care of neonates at risk for complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful observation of infants whose second degree atrioventricular block has been reversed in utero is necessary in the postnatal period, as there is still a risk of progression to a higher degree heart block, even with clearance of maternal autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/93\">",
"     93",
"    </a>",
"    ]. If prenatal screening or fetal monitoring has detected any degree of heart block in utero, consultation with a pediatric cardiologist should be obtained. Some infants with complete heart block will require insertion of a cardiac pacemaker, especially if the heart rate at delivery is less than 55 beats per minute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An electrocardiogram (ECG) should be performed in all neonates born to mothers with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies to detect first degree heart block; infants with first degree heart block are at risk of postnatal progression to higher degree block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. A normal ECG is reassuring.",
"   </p>",
"   <p>",
"    Prolonged in utero exposure to fluorinated glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) can lead to adrenal hypoplasia and result in neonatal adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/94\">",
"     94",
"    </a>",
"    ]. This is a rare complication that can be anticipated and tested for. Neonatal hypotension that potentially results from adrenal insufficiency should be treated empirically with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    in addition to standard supportive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Early outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rash of neonatal lupus (NL) generally does not cause scarring and disappears within six to eight months. Appearance of NL skin lesions postnatally is independent of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/95\">",
"     95",
"    </a>",
"    ]. Thus, breastfeeding is not contraindicated in mothers with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-SSB/La",
"    </span>",
"    antibodies.",
"   </p>",
"   <p>",
"    There is little risk of later cardiac involvement in patients who had no evidence of heart block of any degree at birth or who had noncardiac manifestations of NL (rash or",
"    <span class=\"nowrap\">",
"     hematologic/liver",
"    </span>",
"    abnormalities) at the time of diagnosis. However, infants with noncardiac manifestations of NL should at least have an ECG, and possibly an echocardiogram, since first degree block is clinically silent and can progress postnatally. There have been no reported cases, nor has the Research Registry for Neonatal Lupus recorded the occurrence, of subsequent development of heart block following documentation of a normal electrocardiogram. As noted previously, second degree block detected in utero, and first or second degree heart block found at birth, can progress to complete heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Heart block'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Congenital complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early outcome in infants with complete heart block was assessed in two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center experience, the mortality varied with the time of presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/44\">",
"       44",
"      </a>",
"      ]. Among 29 cases diagnosed in utero by fetal echocardiography, there was one therapeutic abortion, six intrauterine deaths, and six deaths within one week of birth (43 percent total mortality). Among 33 cases diagnosed in the neonatal period, there were no neonatal deaths, but two died before age two (6 percent mortality). Among the survivors, 89 percent were ultimately paced.",
"     </li>",
"     <li>",
"      An early report from the Research Registry for Neonatal Lupus included 105 mothers with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies who had 113 infants with congenital complete heart block [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/47\">",
"       47",
"      </a>",
"      ]. The overall mortality was 19 percent; 5 percent occurred in utero, 9 percent within the first three months of birth, and 5 percent between the age of three months and three years. As in the above report, there were no deaths older than the age of three. Sixty-three percent of surviving affected infants ultimately required a pacemaker.",
"     </li>",
"     <li>",
"      In a United States based cohort of 325 cases with cardiac manifestations of NL, the case fatality rate was 17.5 percent. Fetal echocardiographic risk factors associated with increased mortality in a multivariable analysis of all cases included hydrops and endocardial fibroelastosis. Significant predictors of in utero death were hydrops and earlier diagnosis, and of postnatal death were hydrops, endocardial fibroelastosis, and lower ventricular rate. There was a significantly higher case fatality rate in minorities compared with whites, who were at a lower risk of hydrops and endocardial fibroelastosis. In a European based cohort of 162 cases with atrioventricular block (80 percent exposed to maternal autoantibodies), 91 percent were alive at birth, and subsequent survival in the neonatal period was 93 percent. Survival was similar in glucocorticoid-treated and untreated fetuses, regardless of degree of block",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      presence of",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA.",
"      </span>",
"      Variables associated with death were gestational age &lt;20 weeks, ventricular rate &le;50 bpm, fetal hydrops, and impaired left ventricular function at diagnosis. The presence of one or more of these variables was associated with a 10-fold increase in mortality before birth and a sixfold increase in mortality in the neonatal period independent of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/96,97\">",
"       96,97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Long-term prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children with complete heart block who are asymptomatic usually remain well until later childhood, adolescence, or adulthood. However, exercise limitation and even death are possible in the absence of pacing. The prognosis following pacemaker implantation is excellent for most children, although development of heart failure may occur. The prognosis of patients with complete heart block is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital third degree (complete) atrioventricular block\", section on 'Long-term prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who have had NL may be at increased risk of developing an autoimmune",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rheumatic disease, albeit this is rare. In a cohort of 49 children followed to at least the age of eight years, six patients (12 percent) developed a well-defined systemic rheumatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/98\">",
"     98",
"    </a>",
"    ]. The disorders noted in these children included pauciarticular and polyarticular onset juvenile idiopathic arthritis, psoriasis, thyroid disease, iritis, type 1 diabetes mellitus, and nephrotic syndrome. None of the children with neonatal disease, nor any of their unaffected siblings, developed systemic lupus erythematosus during at least eight years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MATERNAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic mothers or those with mild symptoms who have children with NL are at risk for maternal progression of autoimmune disease, most commonly Sj&ouml;gren syndrome. The development of lupus nephritis in mothers of children with NL is relatively uncommon. In a review of the database of the Research Registry for Neonatal Lupus, 50 percent of mothers had some progression of their health status toward development of autoimmune (rheumatologic) symptoms. These asymptomatic mothers had a 19 percent risk of developing SLE and a 28 percent chance of developing probable or definite Sj&ouml;gren syndrome within 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/3\">",
"     3",
"    </a>",
"    ]. The NL manifestations were not predictive of maternal disease progression.",
"   </p>",
"   <p>",
"    The prevalence of hypothyroidism may be increased among women with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies as indicated in data from a prospective study of 87 women with such antibodies, of whom nine either were hypothyroid or had a history of hypothyroidism (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/99\">",
"     99",
"    </a>",
"    ]. In addition, the incidence of complete congenital heart block in the offspring of the nine women with hypothyroidism was significantly higher than in those without (56 percent versus 13 percent). The presence of antithyroid antibodies is not unexpected in women with an autoimmune diathesis.",
"   </p>",
"   <p>",
"    Thyroid abnormalities were also observed in a study from the Research Registry for Neonatal Lupus in which 11 of 69 mothers (16 percent) with children with NL had clinical thyroid disease (nine with hypothyroidism and two with hyperthyroidism) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/57/24474/abstract/100\">",
"     100",
"    </a>",
"    ]. In addition, 23 mothers (33 percent) had anti-thyroglobulin antibodies, and 15 (22 percent) had anti-thyroperoxidase antibodies. This study did not evaluate mothers with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies who only had healthy children. However, mothers with these thyroid abnormalities who had children with NL also gave birth to normal children. A mechanistic explanation for such an association between neonatal lupus and anti-thyroid antibodies is not apparent at this time. However, evaluation of thyroid disorders is warranted in any mother of an infant with neonatal lupus who complains of hair loss or fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27193234\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal lupus is a passively acquired autoimmune disease that occurs in offspring of mothers with",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies. The risk of having a child with complete heart block in these mothers is two percent for first pregnancies or if previous babies were healthy. The risk increases ten- and five-fold, respectively, if a previous child had complete heart block or cutaneous neonatal lupus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary clinical features are a photosensitive rash that is usually found on the scalp and periorbital areas",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart block. The large majority of cases of congenital complete heart block, absent major structural abnormalities, that are diagnosed in utero or in the neonatal period are associated with maternal",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      antibodies. Another cardiac manifestation that can occur in isolation or more commonly with heart block is cardiomyopathy, the presence of which increases the risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      demise. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"       \"Congenital third degree (complete) atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis is usually made in utero in mothers with autoimmune disease who screened positive for",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-SSB/La",
"      </span>",
"      antibodies. There are no formal guidelines for the type or the frequency of testing to detect fetal heart block in these women, but weekly pulsed Doppler fetal echocardiography from the 18th through the 26th week of pregnancy and then every other week until 32 weeks is often advised. The detection of a slow fetal heart rate and subsequent echocardiographic confirmation of heart block, even in an asymptomatic woman warrants immediate maternal testing for",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       SSB/La",
"      </span>",
"      antibodies. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prenatal treatment with fluorinated glucocorticoids (oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      4 mg per day or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      3 mg per day) for mothers of fetuses with second degree heart block, beginning as soon after detection as is feasible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is done in accordance with the hypothesis that incomplete block represents a reversible inflammatory state and not a complete scar. The challenge is the decision of when to stop such therapy. If the fetus improves, continuing therapy through the end of pregnancy is reasonable. If the fetus progresses to third degree block or fails to respond, discontinuation of therapy is reasonable if there is no other indication (eg, cardiomyopathy) for treatment with glucocorticoids. Cardiomyopathy associated with neonatal lupus is also typically treated with glucocorticoids. Treatment of third degree block without any signs of myocarditis with glucocorticoids is generally",
"      <strong>",
"       not",
"      </strong>",
"      advised, since reversal has not been documented. Most of these patients will require cardiac pacing. Treatment of first degree block is perhaps the most controversial. The cutoff for the definition of first degree block is relevant. If the PR interval is greater than 150 msec, at least a short course of glucocorticoids is an option. Some clinicians may advise not treating with glucocorticoids, because of the risks of therapy and absence of consistent evidence regarding benefit. (See",
"      <a class=\"local\" href=\"#H4218950\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"       \"Congenital third degree (complete) atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest preemptive treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (400 mg orally once a day) in pregnant women who have previously given birth to a child with cardiac manifestations of neonatal lupus (cardiac-NL) and who have",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro",
"      </span>",
"      antibodies, regardless of maternal health status (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Hydroxychloroquine should be initiated between 6 and 10 weeks gestation in women who are not already on the medication. Use of hydroxychloroquine in pregnant women with autoimmune disease (eg, systemic lupus erythematosus, Sj&ouml;gren syndrome) is discussed separately. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Preemptive treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H3#H3\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Hydroxychloroquine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The rash of neonatal lupus generally does not cause scarring and disappears within six to eight months. There appears to be no risk of later cardiac involvement in patients who had no evidence of heart block of any degree in utero or at birth. Second degree block detected in utero, and first or second degree heart block found at birth, can progress to complete heart block. Infants and young children with complete heart block usually require a pacemaker at some point in life. The prognosis following pacemaker implantation is excellent for most children, although development of heart failure may occur. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Course'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link&amp;anchor=H12#H12\">",
"       \"Congenital third degree (complete) atrioventricular block\", section on 'Long-term prognosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/1\">",
"      Brucato A, Cimaz R, Caporali R, et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/2\">",
"      Buyon JP. Updates on lupus and pregnancy. Bull NYU Hosp Jt Dis 2009; 67:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/3\">",
"      Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009; 68:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/4\">",
"      Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001; 44:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/5\">",
"      Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/6\">",
"      Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/7\">",
"      Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/8\">",
"      Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/9\">",
"      Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/10\">",
"      Micha&euml;lsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/11\">",
"      Buyon JP, Winchester RJ, Slade SG, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/12\">",
"      Stea EA, Routsias JG, Clancy RM, et al. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006; 54:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/13\">",
"      Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/14\">",
"      Izmirly PM, Llanos C, Lee LA, et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010; 62:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/15\">",
"      Buyon J, Roubey R, Swersky S, et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988; 15:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/16\">",
"      Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/17\">",
"      Jaeggi E, Laskin C, Hamilton R, et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/18\">",
"      Silverman ED, Buyon J, Laxer RM, et al. Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. Clin Exp Immunol 1995; 100:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/19\">",
"      Salomonsson S, D&ouml;rner T, Theander E, et al. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/20\">",
"      Salomonsson S, Sonesson SE, Ottosson L, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/21\">",
"      Clancy RM, Buyon JP, Ikeda K, et al. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005; 52:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/22\">",
"      Strandberg L, Winqvist O, Sonesson SE, et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008; 154:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/23\">",
"      Ho SY, Esscher E, Anderson RH, Micha&euml;lsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986; 58:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/24\">",
"      Alexander E, Buyon JP, Provost TT, Guarnieri T. Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 1992; 35:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/25\">",
"      Neufing PJ, Clancy RM, Jackson MW, et al. Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum 2005; 52:3934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/26\">",
"      Clancy RM, Neufing PJ, Zheng P, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006; 116:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/27\">",
"      Miranda-Car&uacute;s ME, Askanase AD, Clancy RM, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 2000; 165:5345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/28\">",
"      Clancy R, Molad Y, Kapur R, et al. Histologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathogenesis of congenital heart block (abstract). Arthritis Rheum 2002; 46:S394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/29\">",
"      Clancy RM, Askanase AD, Kapur RP, et al. Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 2002; 169:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/30\">",
"      Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/31\">",
"      Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block. Circulation 2001; 103:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/32\">",
"      Karnabi E, Qu Y, Mancarella S, Boutjdir M. Rescue and worsening of congenital heart block-associated electrocardiographic abnormalities in two transgenic mice. J Cardiovasc Electrophysiol 2011; 22:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/33\">",
"      Provost TT, Watson R, Gammon WR, et al. The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. N Engl J Med 1987; 316:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/34\">",
"      Sheth AP, Esterly NB, Ratoosh SL, et al. U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies? Br J Dermatol 1995; 132:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/35\">",
"      Acherman RJ, Friedman DM, Buyon JP, et al. Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies. Prenat Diagn 2010; 30:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/36\">",
"      Sir&eacute;n MK, Julkunen H, Kaaja R, et al. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus 1999; 8:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/37\">",
"      Clancy RM, Marion MC, Kaufman KM, et al. Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum 2010; 62:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/38\">",
"      Clancy RM, Backer CB, Yin X, et al. Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum 2004; 50:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/39\">",
"      Stevens AM, Hermes HM, Rutledge JC, et al. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003; 362:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/40\">",
"      Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol 2010; 72:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/41\">",
"      Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/42\">",
"      Lee LA. Neonatal lupus: clinical features, therapy, and pathogenesis. Curr Rheumatol Rep 2001; 3:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/43\">",
"      Pe&ntilde;ate Y, Guillermo N, Rodr&iacute;guez J, et al. Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review. J Cutan Pathol 2009; 36:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/44\">",
"      Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/45\">",
"      Johansen AS, Herlin T. [Neonatal lupus syndrome. Association with complete congenital atrioventricular block]. Ugeskr Laeger 1998; 160:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/46\">",
"      Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/47\">",
"      Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/48\">",
"      Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/49\">",
"      Jaeggi ET, Silverman ED, Laskin C, et al. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol 2011; 57:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/50\">",
"      Chockalingam P, Jaeggi ET, Rammeloo LA, et al. Persistent fetal sinus bradycardia associated with maternal anti-SSA/Ro and anti-SSB/La antibodies. J Rheumatol 2011; 38:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/51\">",
"      Brucato A, Previtali E, Ramoni V, Ghidoni S. Arrhythmias presenting in neonatal lupus. Scand J Immunol 2010; 72:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/52\">",
"      Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/53\">",
"      Cuneo BF, Strasburger JF, Niksch A, et al. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease. J Matern Fetal Neonatal Med 2009; 22:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/54\">",
"      Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/55\">",
"      Cimaz R, Stramba-Badiale M, Brucato A, et al. QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block. Arthritis Rheum 2000; 43:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/56\">",
"      Falcini F, De Simone L, Donzelli G, Cerinic MM. Congenital conduction defects in children born to asymptomatic mothers with anti-SSA/SSB antibodies: report of two cases. Ann Ital Med Int 1998; 13:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/57\">",
"      Houssiau FA, Lebacq EG. Neonatal lupus erythematosus with congenital heart block associated with maternal systemic lupus erythematosus. Clin Rheumatol 1986; 5:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/58\">",
"      Fu LS, Hwang B, Lee BH. Newborns of Chinese mother with systemic lupus erythematosus (SLE). Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992; 33:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/59\">",
"      Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/60\">",
"      Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/61\">",
"      Guettrot-Imbert G, Cohen L, Fermont L, et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies. J Rheumatol 2011; 38:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/62\">",
"      Ferrazzini G, Fasnacht M, Arbenz U, et al. Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valve. Intensive Care Med 1996; 22:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/63\">",
"      Kim KR, Yoon TY. A case of neonatal lupus erythematosus showing transient anemia and hepatitis. Ann Dermatol 2009; 21:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/64\">",
"      Lynn Cheng C, Galbraith S, Holland K. Congenital lupus erythematosus presenting at birth with widespread erosions, pancytopenia, and subsequent hepatobiliary disease. Pediatr Dermatol 2010; 27:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/65\">",
"      Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002; 109:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/66\">",
"      Yuan TM, Chen LH, Yu HM. Neonatal lupus erythematosus: three case reports and review of the Chinese literature. Clin Pediatr (Phila) 2010; 49:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/67\">",
"      Wolach B, Choc L, Pomeranz A, et al. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child 1993; 147:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/68\">",
"      Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/69\">",
"      Askanase AD, Izmirly PM, Katholi M, et al. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus 2010; 19:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/70\">",
"      Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/71\">",
"      Zhao H, Cuneo BF, Strasburger JF, et al. Electrophysiological characteristics of fetal atrioventricular block. J Am Coll Cardiol 2008; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/72\">",
"      Gardiner HM, Belmar C, Pasquini L, et al. Fetal ECG: a novel predictor of atrioventricular block in anti-Ro positive pregnancies. Heart 2007; 93:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/73\">",
"      Askanase A, Friedman D, Glickstein J, et al. Potential therapeutic window from normal heart rate (NHR) to advanced heart block and early detection of first degree block by echocardiographic measurement of the mechanical PR interval. Arthritis Rheum 2002; 46:S321 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/74\">",
"      Vesel S, Mazi U, Blejec T, Podnar T. First-degree heart block in the fetus of an anti-SSA/Ro-positive mother: reversal after a short course of dexamethasone treatment. Arthritis Rheum 2004; 50:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/75\">",
"      Sonesson SE, Salomonsson S, Jacobsson LA, et al. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/76\">",
"      Buyon JP, Askanase AD, Kim MY, et al. Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum 2005; 52:1341.",
"     </a>",
"    </li>",
"    <li>",
"     Silverman ED. Neonatal lupus. In: Textbook of pediatric rheumatology, Cassidy JT, Petty RE (Eds), WB Saunders, Philadelphia 2001. p.456.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/78\">",
"      Simell O, Perheentupa J, Rapola J, et al. Lysinuric protein intolerance. Am J Med 1975; 59:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/79\">",
"      Palac&iacute;n M, Borsani G, Sebastio G. The molecular bases of cystinuria and lysinuric protein intolerance. Curr Opin Genet Dev 2001; 11:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/80\">",
"      Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999; 42:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/81\">",
"      Yamada H, Kato EH, Ebina Y, et al. Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature. Am J Reprod Immunol 1999; 42:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/82\">",
"      Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/83\">",
"      Rein AJ, Mevorach D, Perles Z, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009; 119:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/84\">",
"      Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/85\">",
"      Breur JM, Visser GH, Kruize AA, et al. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004; 24:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/86\">",
"      Hutter D, Silverman ED, Jaeggi ET. The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro/SSA antibodies: a review. Scand J Immunol 2010; 72:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/87\">",
"      Mevorach D, Elchalal U, Rein AJ. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. Curr Opin Rheumatol 2009; 21:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/88\">",
"      Trucco SM, Jaeggi E, Cuneo B, et al. Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy. J Am Coll Cardiol 2011; 57:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/89\">",
"      Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/90\">",
"      Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/91\">",
"      Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/92\">",
"      Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/93\">",
"      Lawrence S, Luy L, Laxer R, et al. The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block. Am J Med 2000; 108:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/94\">",
"      Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003; 62:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/95\">",
"      Klauninger R, Skog A, Horvath L, et al. Serologic follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus 2009; 18:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/96\">",
"      Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/97\">",
"      Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/98\">",
"      Martin V, Lee LA, Askanase AD, et al. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/99\">",
"      Spence D, Hornberger L, Hamilton R, Silverman ED. Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. J Rheumatol 2006; 33:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/57/24474/abstract/100\">",
"      Askanase AD, Iloh I, Buyon JP. Hypothyroidism and antithyroglobulin and antithyroperoxidase antibodies in the pathogenesis of autoimmune associated congenital heart block. J Rheumatol 2006; 33:2099.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6402 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24474=[""].join("\n");
var outline_f23_57_24474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27193234\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - 52 kD component of SSA/Ro",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Role in cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Role in heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4219179\">",
"      In utero monitoring for heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4219069\">",
"      Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4219076\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4218950\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treating fetal heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Preemptive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Care of neonates at risk for complete heart block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Early outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Congenital complete heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Long-term prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MATERNAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27193234\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_57_24475="RINV guidelines";
var content_f23_57_24475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiotherapy-induced nausea and vomiting: MASCC/ESMO 2010 and ASCO 2011 guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Risk level",
"      </td>",
"      <td class=\"subtitle1\">",
"       Risk factors",
"      </td>",
"      <td class=\"subtitle1\">",
"       Antiemetic guidelines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       TBI",
"      </td>",
"      <td>",
"       Prophylaxis with 5-HT3-RA + DEX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moderate",
"      </td>",
"      <td>",
"       Upper abdomen, HBI, UBI",
"      </td>",
"      <td>",
"       Prophylaxis with 5-HT3-RA + optional DEX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       Cranium (all), craniospinal, H &amp; N, lower thorax region, pelvis",
"      </td>",
"      <td>",
"       Prophylaxis or rescue with 5-HT3-RA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Minimal",
"      </td>",
"      <td>",
"       Extremities, breast",
"      </td>",
"      <td>",
"       Rescue with dopamine receptor antagonist or 5-HT3-RA",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ASCO: American Society of Clinical Oncology; MASCC: Multinational Association for Supportive Care in Cancer; ESMO: European Society of Medical Oncology; TBI: total body irradiation; HBI: half body irradiation; UBI: upper body irradiation; 5-HT3-RA: 5-HT3-receptor-antagonist; DEX: dexamethasone.",
"     <br>",
"      * In concomitant radiochemotherapy the antiemetic prophylaxis is according to the chemotherapy-related antiemetic guidelines of the corresponding risk category, unless the risk of emesis is higher with radiotherapy than chemotherapy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24475=[""].join("\n");
var outline_f23_57_24475=null;
var title_f23_57_24476="Opioid dosing guideline";
var content_f23_57_24476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opioid dosing guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Opioids have no ceiling effect for analgesia. Dosing may be limited by side effects. The appropriate dose is the one needed to control the patient's pain with the fewest side effects. Combination products containing acetaminophen, aspirin or ibuprofen are limited by the maximum dose of the non-opioid ingredients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients who chronically use opioids need prophylaxis against opioid-induced constipation, unless medically contraindicated. (See Constipation algorithm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients using sustained release opioids usually require a short acting opioid for breakthrough pain.",
"        <strong>",
"         Each dose of the breakthrough opioid should equal 10-15 percent of the total daily requirement of sustained release opioid",
"        </strong>",
"        (eg, sustained release morphine 150 mg by mouth every 12 hours with immediate release morphine 30-45 mg by mouth every 3 hours as needed for pain). Some clinicians do not use breakthrough doses for non-malignant pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If more than 3-4 doses of breakthrough medication are used daily for chronic pain, increase the dose of the sustained release opioid by an amount equal to 50-100 percent of the total amount of breakthrough medication used in 24 hours. (eg, A patient takes sustained release morphine 150 mg by mouth every 12 hours plus 5 doses of immediate release morphine 45 mg in 24 hours. Increase the total MS Contin&reg; dose by 112.5 to 225 mg according to the patient's status and pain intensity).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In a patient with well-controlled pain, when calculating the initial dose of a new opioid in opioid rotation, some authorities recommend reducing the dose by 25-50 percent to account for incomplete cross-tolerance among opioids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Naloxone reverses respiratory depression, sedation and ANALGESIA.",
"        </strong>",
"        In patients on chronic opioid therapy, reserve Naloxone use for life threatening respiratory depression unresponsive to dose reduction and appropriate respiratory support. Administer cautiously to avoid withdrawal symptoms and severe pain.",
"        <strong>",
"         Titrate dose to improvement in respiratory function and sedation.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dilute 0.4 mg (1 ml of a 0.04 mg/ml ampoule of naloxone) in 9 ml normal saline for final concentration of 0.04 mg/ml.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Administer intravenous push cautiously, 0.04 mg/1 ml - 0.08 mg/2 ml at a time, to avoid withdrawal symptoms. Usual dose: 0.04-0.08 mg every 60 seconds, titrating to effect (ie, sedation/respiratory depression is beginning to reverse).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Repeated doses may be required because naloxone's duration of action is shorter than that of opioid agonists.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     mg: milligrams; ml: milliliters.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pain Management Tables and Guidelines. Dana Farber Cancer Institute/Brigham and Women's Hospital Pain and Pallitative Care Program. Copyright &copy; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24476=[""].join("\n");
var outline_f23_57_24476=null;
var title_f23_57_24477="Percent change BMD older men";
var content_f23_57_24477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in bone mineral density in older men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annualized percentage change in bone mineral density, measured by dual energy x-ray absorptiometry (DXA), in elderly men measured in the mid-lateral lumbar spine, femoral neck, or anterior-posterior lumbar spine projections. Bone density measured in the anterior-posterior (AP) projection, appears to increase. This is probably due to degenerative changes in the posterior spinous elements. Thus, anterior-posterior DXA is a poor technique for assessing bone density in older men.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with modifications from: Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 2000; 15:1417.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24477=[""].join("\n");
var outline_f23_57_24477=null;
var title_f23_57_24478="CRH family neuropeptides";
var content_f23_57_24478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    CRH family of neuropeptides and receptors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George P Chrousos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24478=[""].join("\n");
var outline_f23_57_24478=null;
var title_f23_57_24479="Umbilical cord cyst";
var content_f23_57_24479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Umbilical cord cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Yves Jacquemyn, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_57_24479=[""].join("\n");
var outline_f23_57_24479=null;
